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Abstract	40 
The	analysis	of	illicit	drugs	in	urban	wastewater	is	the	basis	of	wastewater-based	41 
epidemiology	 (WBE),	 and	 has	 received	 much	 scientific	 attention	 because	 the	42 
concentrations	measured	can	be	used	as	a	new	non-intrusive	tool	to	provide	evidence-43 
based	and	real-time	estimates	of	community-wide	drug	consumption.	Moreover,	WBE	44 
allows	 monitoring	 patterns	 and	 spatial	 and	 temporal	 trends	 of	 drug	 use.	 Although	45 
information	and	expertise	 from	other	disciplines	 is	 required	 to	 refine	and	effectively	46 
apply	 WBE,	 analytical	 chemistry	 is	 the	 fundamental	 driver	 in	 this	 field.	 The	 use	 of	47 
advanced	analytical	techniques,	commonly	based	on	combined	chromatography	-	mass	48 
spectrometry,	 is	 mandatory	 because	 the	 very	 low	 analyte	 concentration	 and	 the	49 
complexity	 of	 samples	 (raw	 wastewater)	 make	 quantification	 and	 identification/	50 
confirmation	of	illicit	drug	biomarkers	(IDBs)	troublesome.		51 
We	review	the	most-recent	literature	available	(mostly	from	the	last	five	years)	52 
on	the	determination	of	IDBs	in	wastewater	with	particular	emphasis	on	the	different	53 
analytical	 strategies	applied.	The	predominance	of	 liquid	chromatography	coupled	to	54 
tandem	mass	spectrometry	to	quantify	target	IDBs	and	the	essence	to	produce	reliable	55 
and	 comparable	 results	 is	 illustrated.	 Accordingly,	 the	 importance	 to	 perform	 inter-56 
laboratory	exercises	and	the	need	to	analyze	appropriate	quality	controls	in	each	sample	57 
sequence	 is	 highlighted.	 Other	 crucial	 steps	 in	 WBE,	 such	 as	 sample	 collection	 and	58 
sample	pre-treatment,	are	briefly	and	carefully	discussed.	The	article	further	focuses	on	59 
the	potential	of	high-resolution	mass	spectrometry.	Different	approaches	for	target	and	60 
non-target	 analysis	 are	 discussed,	 and	 the	 interest	 to	 perform	 experiments	 under	61 
laboratory-controlled	 conditions,	 as	 a	 complementary	 tool	 to	 investigate	 related	62 
compounds	(e.g.,	minor	metabolites	and/or	transformation	products	in	wastewater)	is	63 
treated.	The	article	ends	up	with	the	trends	and	future	perspectives	in	this	field	from	64 
the	authors’	point	of	view.	65 
Keywords:	Mass	spectrometry,	Drugs	of	abuse,	Urinary	Metabolites,	Wastewater-based	66 
epidemiology		67 
68 
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1. Introduction	69 
Illicit	 drug	 use	 is	 a	 global	 problem	 with	 severe	 consequences,	 not	 only	 for	70 
people´s	health	and	welfare,	but	also	as	a	clear	threat	to	the	stability	and	security	of	71 
entire	 regions	 and	 economic	 and	 social	 development.	 Accordingly,	 there	 is	 a	72 
considerable	 financial	 cost	 related	 to	 illicit	 drug	 use,	 associated	 with	 drug	 use	73 
prevention,	treatment	of	addicts,	and	on	the	fight	against	organized	crime	(EMCDDA,	74 
2012;	 Nutt	 et	 al.,	 2007;	 UNODC,	 2014).	 Policy	 makers	 need	 accurate	 and	 reliable	75 
information	on	the	use	of	these	substances	in	order	to	make	evidence-based	decisions	76 
and	to	effectively	allocate	resources.	The	prevalence	of	illicit	drug	use	has	traditionally	77 
been	 estimated	with	 direct	 subjective	methods,	 like	 general	 population	 surveys	 and	78 
interviews,	and	indirect	methods	such	as	monitor	drug-related	criminality,	seizures,	and	79 
hospital	 records	 (EMCDDA,	2015a).	Despite	considerable	 improvements	with	modern	80 
communication	 facilities,	 and	 the	 use	 of	 complementary	 methods	 such	 as	 targeted	81 
studies	and	statistical	modeling,	these	survey	methods	mainly	rely	on	the	willingness	of	82 
users	to	self-report	and	to	monitor	actions.	However,	the	social	taboo	related	to	illicit	83 
drug	 use	 might	 provoke	 non-participation	 and	 false	 responses	 in	 such	 surveys	 that	84 
makes	 these	methods	 vulnerable	 and	 potentially	 inaccurate.	 In	 addition,	 a	 common	85 
challenge	with	such	methods	is	that	they	are	time-consuming,	expensive,	and	complex	86 
(Banta-Green	and	Field,	2011).	Therefore,	the	development	of	new	and	complementary	87 
approaches	 is	 encouraged	 in	 order	 to	 obtain	 objective,	 low-cost,	 fast,	 reliable,	 and	88 
comparable	data.	89 
The	 chemical	 analysis	 of	 illicit	 drug	 residues	 in	 untreated	wastewater	 is	 as	 a	90 
valuable	tool	to	complement	existing	approaches	to	monitor	spatiotemporal	patterns	91 
and	trends	of	illicit	drug	use	in	large	communities	(EMCDDA,	2015b;	Ort	et	al.,	2014c;	92 
Thomas	et	al.,	2012;	Zuccato	et	al.,	2008).	This	approach	is	termed	wastewater-based	93 
epidemiology	(WBE),	and	relies	on	the	principle	that	illicit	drugs	consumed	by	individuals	94 
are	 excreted,	 either	 unchanged	 or	 as	 a	 mixture	 of	 metabolites,	 into	 urban	 sewer	95 
networks.	The	quantitative	measurement	of	these	specific	illicit	drug	biomarkers	(IDBs)	96 
in	wastewater	samples	reflects	the	drugs	collectively	excreted	by	users	and	enables	data	97 
to	be	gathered	on	drug	use	by	the	community	within	the	geographical	boundary	defined	98 
by	the	catchment	area	of	a	wastewater	treatment	plant	(WWTP).	Several	crucial	steps	99 
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are	 involved	 in	 this	 approach	 (Fig.	 1.),	 which	 requires	 significant	 expertise	 from	100 
numerous	research	fields,	and	therefore,	strong	multi-disciplinary	collaboration		(Ort	et	101 
al.,	2014a).	102 
	103 
	104 
	105 
Figure	1.	Main	consecutive	steps	of	the	WBE	approach	and	data	required	for	each	step	106 
(modified	from	(Castiglioni	et	al.,	2014)).	107 
	108 
The	WBE	concept	was	initially	proposed	by	Daughton	in	2001	(Daughton,	2001)	109 
and	first	applied	in	2005	through	the	estimation	of	cocaine	use	in	Italy	(Zuccato	et	al.,	110 
2005).	 Since	 then,	WBE	 has	 expanded	 to	 include	 other	 illicit	 drugs,	 such	 as	 heroin,	111 
cannabis,	and	amphetamine-like	stimulants	(Castiglioni	et	al.,	2014;	EMCDDA,	2015b;	112 
van	Nuijs	et	al.,	2011)	and	new	psychoactive	substances	(NPS)		(Kinyua	et	al.,	2015;	Reid	113 
et	 al.,	 2014b;	 van	 Nuijs	 et	 al.,	 2014).	 Data	 have	 also	 been	 reported	 for	WBE-based	114 
analysis	of	alcohol	(Boogaerts	et	al.,	2016;	Mastroianni	et	al.,	2014;	Reid	et	al.,	2011;	115 
Rodríguez-Álvarez	et	al.,	2015,	2014),	tobacco	(Castiglioni	et	al.,	2015;	Rodriguez-Alvarez	116 
et	al.,	2014;	B.	J.	Tscharke	et	al.,	2016),	and	counterfeit	medicines	(Venhuis	et	al.,	2014).		117 
An	 important	 step	 in	 the	 progression	 of	 WBE	 was	 accomplished	 with	 the	118 
establishment	 of	 a	 European-wide	 network	 (Sewage	 analysis	 CORe	 group	 Europe	 –	119 
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SCORE),	 supported	by	 the	 European	Monitoring	Centre	 for	Drug	 and	Drug	Addiction	120 
(EMCDDA)	 (EMCDDA,	 2015b).	 This	 network	 has	 since	 2010	 standardized	 the	 WBE	121 
approach,	coordinated	international	studies	(Ort	et	al.,	2014c;	Thomas	et	al.,	2012),	and	122 
conducted	inter-laboratory	exercises	for	quality	control	purposes.	The	latter	provided	a	123 
means	to	estimate	and	critically	assess	the	uncertainty	related	to	the	wastewater-based	124 
estimates	 (Castiglioni	 et	 al.,	 2013).	However,	 important	WBE	 research	has	 also	been	125 
conducted	in	other	continents	such	as	Asia	(Khan	et	al.,	2014;	Kim	et	al.,	2015;	Lai	et	al.,	126 
2013b;	Li	et	al.,	2014),	Australia	(Irvine	et	al.,	2011;	Lai	et	al.,	2013a;	Prichard	et	al.,	2012;	127 
Tscharke	et	al.,	2016,	2015),	North	America	(Banta-Green	et	al.,	2009;	Burgard	et	al.,	128 
2013;	Subedi	and	Kannan,	2014),	and	Central	and	South	America	(Bijlsma	et	al.,	2016;	129 
Devault	 et	 al.,	 2014;	 Maldaner	 et	 al.,	 2012;	 Voloshenko-Rossin	 et	 al.,	 2015).	130 
Furthermore,	 a	 recently	 published	 review	 on	 neuropsychiatric	 pharmaceuticals	 and	131 
illicit	 drugs	 in	 wastewater	 treatment	 plants	 (Asimakopoulos	 and	 Kannan,	 2016)	 is	132 
recommended	for	readers	interested.	133 
The	increasing	interest	of	WBE	is	clearly	illustrated	by	the	number	of	papers	and	134 
citations	 on	 the	 topic	 (>200	 papers	 in	 years	 2005-2015,	 >5000	 citations;	 ISI	Web	 of	135 
Science),	international	conferences	and	workshops	organized	on	this	topic,	and	funding	136 
received	 from	 the	 European	 Commission	 (“http://score-cost.eu/”;	 “http://sewprof-137 
itn.eu/”).		138 
Chemical	analysis	of	IDBs	in	wastewater	plays	an	important	key	role	within	the	139 
WBE	 approach.	 Advanced	 analytical	 techniques	 and	 expertise	 is	 required	 to	 obtain	140 
accurate	concentration	data	on	IDBs	in	wastewater,	because	quantitative	data	are	the	141 
basis	of	subsequent	back-calculations	of	IDB	mass	loads	and	drug	use.	Concentrations	142 
of	IDBs	in	wastewater	samples	are	generally	around	a	factor	1000	lower	than	in	human	143 
biological	 fluids	 (ng/L	 versus	ng/mL),	which	points	out	 the	 challenge	 for	quantitative	144 
analysis.	Low	analyte	concentrations	in	combination	with	the	complexity	and	unknown	145 
composition	of	the	wastewater	matrix	might	hamper	not	only	the	sensitive	and	accurate	146 
quantification	but	also	a	sound	identification.	Chromatography	-	mass	spectrometry	is	147 
the	 best-suited	 approach	 to	 obtain	 the	 sensitivity,	 selectivity,	 and	 identification	148 
requirements	in	chemical	analysis	directed	towards	WBE.	149 
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Gas	chromatography	coupled	to	mass	spectrometry	(GC-MS)	(González-Mariño	150 
et	al.,	2010;	Mari	et	al.,	2009)	in	general	provides	high	levels	of	selectivity	and	sensitivity.	151 
However,	derivatization	of	 the	target	compounds	 is	often	necessary	 for	most	 IDBs	 in	152 
order	 to	 make	 them	 compatible	 with	 GC.	 Consequently,	 sample	 treatment	 and	153 
measurement	 is	 generally	 laborious	 and	 time-consuming.	 Liquid	 chromatography	154 
coupled	 to	mass	 spectrometry	 (LC-MS)	 is	 a	more-versatile	 technique	 that	 allows	 the	155 
determination	of	polar,	low-volatility,	and/or	thermolabile	compounds,	which	most	IDBs	156 
are,	with	less	sample	treatment	and	shorter	chromatographic	analysis	times.	Besides,	157 
the	sample	matrix	(i.e.,	water)	is	completely	compatible	with	this	technique.	LC	-	tandem	158 
mass	spectrometry	(LC-MS/MS),	e.g.	a	triple	quadrupole	(QqQ)	analyzer,	is	even	more	159 
powerful,	and	has	become	the	technique	of	choice	for	the	quantitative	determination	160 
of	(known)	IDBs	in	wastewater	samples	(van	Nuijs	et	al.,	2011).		161 
Despite	 the	 predominance	 of	 LC-MS/MS	 in	 WBE	 studies,	 the	 use	 of	 high-162 
resolution	 mass	 spectrometry	 (HRMS)	 has	 been	 recently	 explored	 and	 opens	 new	163 
perspectives	in	the	analytical	field.	Its	strong	potential	to	screen	and	for	identification	164 
purposes	originates	from	the	acquisition	of	accurate-mass	full-spectrum	data.	LC-HRMS	165 
is	 a	 powerful	 technique	 that	 allows	 the	 wide-scope	 screening	 of	 many	 illicit	 drugs,	166 
metabolites	and	transformation	products,	as	well	as	the	investigation	of	NPS	(Alechaga	167 
et	al.,	2015;	Bade	et	al.,	2015c;	Baz-Lomba	et	al.,	2016;	Bijlsma	et	al.,	2013b;	Hernández	168 
et	 al.,	 2014;	 Ibáñez	 et	 al.,	 2014;	 Reid	 et	 al.,	 2014a).	 There	 are	 several	 illustrative	169 
examples	(as	presented	later	in	this	manuscript)	in	the	most-recent	literature	that	show	170 
that	modern	 analytical	 chemistry	 is	 essential	 in	 order	 to	 increase	 our	 knowledge	 on	171 
trends	in	substance	use	in	the	general	population.	172 
In	 this	 article,	 an	 exhaustive	 review	 of	 the	 existing	 literature	 is	 not	 the	 goal.	173 
Rather,	the	objective	is	to	present	an	overview	of	the	approach	by	using	the	most-recent	174 
literature	available,	with	specific	emphasis	on	the	different	analytical	strategies	applied	175 
for	WBE.	Most	cited	papers	have	been	published	within	the	last	five	years,	except	for	176 
some	that	have	also	been	included	because	of	their	relevance	in	the	development	of	the	177 
WBE	approach.	The	predominance	of	LC-MS/MS	to	quantify	priority,	well-known,	target	178 
IDBs	 and	 the	 essence	 to	 produce	 reliable	 and	 comparable	 results	 are	 illustrated.	179 
Accordingly,	 the	 importance	 to	 perform	 inter-laboratory	 exercises	 and	 the	 need	 to	180 
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analyze	 appropriate	 quality	 controls	 in	 each	 sample	 sequence	 is	 highlighted.	 Other	181 
crucial	steps	related	to	WBE,	such	as	sample	collection	and	sample	pre-treatment,	are	182 
discussed.	 The	 article	 further	 focuses	 on	 novel	 analytical	 approaches,	 such	 as	183 
enantiomeric	profiling,	the	different	strategies	for	target	and	non-target	analysis	with	184 
LC-HRMS,	and	on	the	interest	to	perform	in	vivo	or	in	vitro	metabolism	experiments	and	185 
degradation	 laboratory	 experiments,	 as	 a	 useful	 tool	 to	 investigate	metabolites	 and	186 
transformation	products	in	wastewater.	The	article	concludes	with	the	trends	and	future	187 
perspectives	in	this	discipline	from	the	authors’	point	of	view.	188 
 189 
2. Target	and	non-target	approaches		190 
The	 terms	 target	 and	 non-target	 analyses	 are	 widely	 employed	 in	 analytical	191 
chemistry.	Other	expressions,	such	as	investigation	of	unknowns	or	suspect	screening,	192 
are	also	frequently	used,	and	illustrate	the	analytical	challenges	in	complex	fields,	such	193 
as	 environmental	 analytical	 chemistry	 (Bletsou	 et	 al.,	 2015;	 Krauss	 et	 al.,	 2010;	194 
Schymanski	et	al.,	2014b).	With	the	 implementation	of	LC-HRMS	 in	several	analytical	195 
fields,	the	term	post-target	analysis	has	been	also	employed,	and	illustrate	the	working	196 
mode	in	which	full-spectrum	accurate-mass	techniques	are	applied	(Hernández	et	al.,	197 
2005).	 Clarification	 of	 these	 terms	 is,	 however,	 necessary	 to	 fully	 understand	 the	198 
different	 strategies	 that	 can	 be	 applied	 to	 investigate	 the	 presence	 of	 IDBs	 in	199 
wastewater	samples.		200 
Target	 methodologies	 are	 commonly	 analyte-dependent;	 i.e.,	 compound-201 
specific	 information	 is	 required	 before	measurement.	 Based	 on	 this	 analyte-specific	202 
information,	highly	 sensitive	and	 selective	analytical	methods	 can	be	developed,	but	203 
other	compounds	that	might	be	present	in	the	samples	will	remain	undetected.	Target	204 
analysis	is	typically	applied	in	methods	based	on	LC	and/or	GC	coupled	to	MS	(Selected	205 
Ion	Monitoring	(SIM)	mode)	or	tandem	MS	(Selected	Reaction	Monitoring	(SRM)	mode).	206 
A	limited	list	of	target	compounds	is	included	in	the	scope	of	the	method,	and	only	those	207 
previously	 selected	 ions/transitions	 are	 monitored.	 Reliable	 identification	 and	208 
quantification	 is	 commonly	 the	main	 objective	 pursued	 in	 this	 type	 of	 analysis.	 This	209 
identification	is	achieved	through	acquisition	of	at	least	three	ions	in	the	SIM	mode	or	210 
two	MS/MS	transitions	in	the	SRM	mode,	and	evaluation	of	retention	time	(tR)	and	ion-211 
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intensity	ratios	(SANTE/11945,	2015).	The	use	of	reference	standards	is	compulsory	with	212 
this	 methodology	 in	 order	 to	 optimize	 the	 mass	 spectrometric	 measurement	213 
parameters	and	for	quantitative	method	validation.	214 
This	methodology	can	also	be	applied	with	HRMS	instruments.	However,	thanks	215 
to	 the	 accurate-mass	 full-spectrum	 acquisition	 at	 good	 sensitivity,	 HRMS	 offers	 the	216 
possibility	to	investigate	the	presence	of	many	other	compounds,	not	only	those	initially	217 
targeted.	Databases	developed	in-house	are	commonly	used	to	facilitate	screening	of	a	218 
large	 number	 of	 compounds	 with	 HRMS.	 The	 information	 included	 in	 the	 database	219 
depends	on	the	availability	of	a	reference	standard.	When	available,	the	information	is	220 
very	complete	(i.e.,	tR,	exact	mass	of	the	(de)protonated	molecule	and/or	adducts,	and	221 
the	main	fragment	ions)	to	highly	facilitate	the	analytical	research.	When	the	reference	222 
standard	is	not	available,	only	limited	information	on	the	target	analytes	can	be	included	223 
in	the	database	(e.g.,	molecular	formula	and	exact	mass,	theoretical	isotope	distribution,	224 
predicted	tR).	Information	reported	in	the	literature	on	product	ions	can	also	be	taken	225 
into	account	to	facilitate	compound	identification.	Even	in	this	worst-case	situation	(i.e.,	226 
when	no	standard	is	available),	accurate-mass	full-spectrum	data	can	be	used	for	the	227 
tentative	 identification	 of	 the	 compounds	 in	 samples	 (Hernández	 et	 al.,	 2015a),	 a	228 
process	where	 the	 interpretation	 and	 justification	 of	 the	 	 fragment	 ions	 observed	 is	229 
crucial.	In	any	case,	the	fact	that	a	search	is	directed	towards	a	list	of	compounds	implies	230 
a	target	approach,	 independent	of	 the	availability	of	reference	standards.	This	 target	231 
approach	is	commonly	known	as	suspect	screening	(Hug	et	al.,	2014;	Krauss	et	al.,	2010)	232 
whereas	other	authors	use	the	term	post-target	(Hernández	et	al.,	2005;	Ibáñez	et	al.,	233 
2008).	234 
Target	analysis	based	on	HRMS	commonly	detects	and	identifies	the	compounds	235 
(i.e.,	 qualitative	 analysis)	 in	wastewater,	 because	HRMS	 really	 takes	 advantage	of	 its	236 
excellent	 performance	 for	 this	 type	 of	 application	 (Hernández	 et	 al.,	 2014,	 2011a).	237 
However,	recent	studies	have	also	been	directed	towards	the	quantitative	analysis	of	238 
IDBs	in	wastewater	(Bijlsma	et	al.,	2013b;	Fedorova	et	al.,	2013;	González-Mariño	et	al.,	239 
2012;	Heuett	et	al.,	2015;	van	der	Aa	et	al.,	2013),	and	a	notable	increase	in	the	number	240 
of	 quantitative	 applications	 of	 HRMS	 that	 pursue	 a	 complete	 analysis	 (i.e.,	 sensitive	241 
detection,	reliable	identification,	accurate	quantification)	is	expected	in	the	near	future.	242 
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A	significant	advantage	of	full-spectrum	acquisitions	is	that	they	also	allow	the	243 
investigation	of	any	other	compound,	not	only	the	 list	of	selected	contaminants,	 in	a	244 
non-target	methodology.	 In	 contrast	 to	 the	 (post-)	 target	 approach,	 a	 genuine	non-245 
target	analysis	does	not	use	any	previous	information	on	the	compounds	to	be	searched	246 
in	the	samples.	Some	authors	use	the	term	non-target	screening	when	they	search	for	247 
unknowns,	which	in	a	strict	sense	starts	without	any	information	on	the	compounds	to	248 
be	 investigated.	 The	 term	 unknown	 does	 not	 necessarily	 mean	 that	 the	 compound	249 
discovered	 in	 the	 analysis	 is	 a	 new	 or	 an	 unreported	 compound.	 Following	 the	250 
elucidation	processes,	 the	unknown	might	turn	out	to	be	a	known	compound,	which	251 
already	has	been	reported	in	the	literature,	but	unexpected	or	not	specifically	searched	252 
for	in	the	samples.	In	a	genuine	non-target	analysis,	there	is	no	analyte	selection	a	priori	253 
(neither	 before	 nor	 after	 MS	 acquisition).	 Under	 these	 circumstances,	 compound	254 
identification	at	trace	levels	in	wastewater	is	a	challenge,	and	commonly	more	than	one	255 
elemental	formula	and	several	plausible	structures	are	obtained	for	a	given	unknown	256 
detected	in	a	sample	(Ibáñez	et	al.,	2008;	Krauss	et	al.,	2010;	Schymanski	et	al.,	2014a).	257 
More	information	on	non-target	analysis	applied	in	the	environmental	field	can	be	found	258 
elsewhere	 (Chiaia-Hernandez	et	al.,	 2014;	Hogenboom	et	al.,	 2009;	Hug	et	al.,	 2014;	259 
Schymanski	et	al.,	2015,	2014b;	van	Leerdam	et	al.,	2014).	260 
Most	 IDBs	are	of	 (medium)	high	polarity;	 therefore,	LC-HRMS	commonly	uses	261 
TOF	and	Orbitrap	analyzers.	The	absence	of	standardized	mass	spectral	libraries	in	LC-262 
MS	 is	an	additional	difficulty	 in	non-target	analysis,	opposite	 to	GC-MS	with	electron	263 
ionization	 (EI),	 where	 the	 availability	 of	 commercial	 libraries	 (e.g.,	 NIST)	 offers	 the	264 
possibility	to	identify	compounds	by	matching	experimental	and	library	spectra.		265 
In	 order	 to	 have	 a	more-realistic	 and	 complete	 overview	 on	 the	 presence	 of	266 
organic	contaminants	in	general,	and	on	IDBs	in	particular,	a	combination	of	target	(both	267 
with	or	without	standards	(i.e.,	suspect	screening)	and	non-target	methodologies	seems	268 
to	be	the	most-attractive	approach	(Hug	et	al.,	2014).	Furthermore,	the	combination	of	269 
GC-HRMS	and	LC-HRMS	(e.g.,	use	the	same	QTOF	instrument	for	both	configurations)	270 
moves	towards	a	more-comprehensive	screening	of	organic	contaminants	in	the	aquatic	271 
environment	independently	of	their	polarity	and	volatility	(Hernández	et	al.,	2015b).	272 
	273 
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3. Sample	collection	approaches	and	sample	preparation	274 
Measurements	with	high-end	instruments	and	sophisticated	statistical	analysis	275 
cannot	 compensate	 or	 reveal	 deficiencies	 in	 sample	 collection.	 Depending	 on	 the	276 
desired	level	of	representativeness	and	accuracy,	sample	collection	is	as	important	as	277 
any	 subsequent	 steps.	 A	 sound	 understanding	 of	 the	 investigated	 environment	 is	278 
imperative	and	must	be	documented	in	detail.	For	most	applications	in	WBE,	the	end	279 
user	 relies	 on	 24-hour	 composite	 influent	 (i.e.,	 raw)	 wastewater	 samples	 collected	280 
routinely	 at	 the	 inlet	 of	 a	 WWTP.	 We	 briefly	 outline	 how	 such	 a	 sample	 is	 ideally	281 
collected	 (sampling)	 and	 how	 many	 samples	 are	 needed	 (monitoring)	 for	 specific	282 
applications.	283 
	284 
3.1. Sampling		285 
The	 number	 of	 consumers	 of	 a	 specific	 substance,	 pharmacokinetics,	 the	286 
population	connected	 to	a	WWTP,	and	 the	hydraulic	properties	of	 the	sewer	system	287 
determine	i)	the	number	of	toilet	flushes	that	contain	the	substance	of	interest,	and	ii)	288 
over	 which	 period	 an	 individual	 toilet	 flush	 expands	 when	 it	 passes	 the	 sampling	289 
location.	These	two	factors	determine	the	temporal	variability	on	the	scale	of	minutes,	290 
which	in	turn	determines	the	required	sampling	frequency	to	collect	a	representative	291 
sample	(i.e.,	how	many	samples	must	be	collected	and	pooled	over	a	certain	period	for	292 
analysis).	Due	to	the	potentially	small	number	of	relevant	toilet	flushes	–	at	least	for	one	293 
of	 multiple	 substances	 analyzed	 in	 the	 collected	 sample	 –	 it	 is	 recommended	 that	294 
sampling	 intervals	do	not	exceed	5-10	minutes	at	 the	 influent	of	 large	WWTPs.	Even	295 
shorter	 sampling	 intervals	of	 1-5	minutes	are	necessary	 for	 composite	 samples	 from	296 
effluents	of	individual	premises.	At	the	effluent	of	e.g.	a	prison,	the	toilet	flushes	extend	297 
over	shorter	periods	and	the	absolute	number	of	substance-related	flushes	is	typically	298 
much	smaller	than	at	the	influent	of	a	(large)	WWTP,	both	leading	to	a	substance	pattern	299 
that	 fluctuates	much	more	 at	 the	 scale	 of	 a	 few	minutes.	 This	 is	 also	 applicable	 to	300 
influents	of	very	small	WWTPs,	where	it	may	be	beneficial	to	sample	from	the	effluent	301 
of	a	primary	treatment	tank,	which	attenuates	temporal	fluctuations	to	some	extent.	302 
However,	please	note	 that	 the	 latter	also	 removes	some	particulate	matter	and	 that	303 
WWTP-internal	recirculation	may	influence	mass	loads	there.	Shorter	sampling	intervals	304 
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are	also	required	for	the	collection	of	representative	samples	that	extend	over	periods	305 
<24h,	e.g.	hourly	composite	samples	to	reliably	assess	diurnal	variations.	Please	note,	306 
grab	samples	to	determine	diurnal	variations	are	not	suitable	because	of	potential	high	307 
short-term	 variations.	 In	 addition,	 intra-day	 variations	 in	 wastewater	 flows	 require	308 
samples	 to	 be	 collected	 in	 a	 flow-	 or	 volume-weighted	 manner.	 More	 details	 and	309 
peculiarities	for	wastewater	sampling	in	sewers,	an	overview	of	relevant	literature,	and	310 
a	list	of	requirements	for	a	series	of	typical	applications	is	described	elsewhere	(Coutu	311 
et	al.,	2016;	De	Keyser	et	al.,	2010;	Ort,	2014;	Ort	et	al.,	2010a,	2010b).		312 
	313 
3.2. Monitoring	314 
Ideally,	one	would	analyze	365	daily	composite	samples	per	year.	Due	to	limited	315 
resources,	 this	 amount	 of	 samples	 is	 usually	 not	 feasible.	 Different	316 
(research/epidemiological)	 questions	 require	 different	 monitoring	 designs,	 and	317 
obviously	 more	 samples	 provide	 higher	 accuracy.	 Random	 day-to-day	 variability,	318 
systematic	 weekly	 cycles,	 and	 seasonal	 fluctuations	 influence	 baseline	 variation.	319 
Together	with	 the	desired	 level	 of	 sensitivity	 and	 significance,	 the	baseline	 variation	320 
determines	the	required	number	and	distribution	of	samples.	To	date,	two	monitoring	321 
design	 studies	 have	 investigated	 different	 approaches	 that	 aim	 to	 answer	 different	322 
questions.		They	are	based	on	a	few	available	long-term	time	series;	i.e.,	data	sets	with	323 
observations	over	more	than	28	consecutive	days.	In	brief,	it	was	found	that	the	baseline	324 
variation	 of	 almost	 all	 investigated	 drug	 residues	 in	 five	 different	 catchments	325 
(population	sizes	that	range	from	approx.	7000	to	1.3	million	people)	did	not	exceed	326 
80%	(as	coefficient	of	variation),	not	accounting	for	any	temporal	correlation	(EMCDDA,	327 
2016).	Based	on	 these	data,	Ort	et	al.	 (Ort	et	al.,	 2014b)	proposed	 that	56	 stratified	328 
random	 samples	 (10	working	 days	 and	 4	weekend	 days	 per	 quarter)	 are	 suitable	 to	329 
estimate	an	annual	mean	with	an	accuracy	of	10%.	Humphries	et	al.	(Humphries	et	al.,	330 
2016)	 evaluated	more	 informed	approaches,	which	 rely	on	 knowledge	about	weekly	331 
cycles.	In	the	presence	of	strong	weekly	cycles	(e.g.,	cocaine	or	MDMA),	it	is	efficient	to	332 
distribute	monitoring	days	systematically	by	considering	peak,	mid,	and	through	usage	333 
days.	 The	 identification	of	weekly	 cycles	 requires	 an	 intensive,	monitoring	period.	 In	334 
return,	the	accuracy,	particularly	of	intra-annual	trends,	improves	the	informed	routine	335 
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monitoring	 compared	 to	 an	 uninformed	 scheme	with	 the	 same	 reduced	 number	 of	336 
samples.	 In	 the	context	 to	assess	effects	of	 interventions,	 the	baseline	variation,	 the	337 
magnitude	of	the	effect	to	be	shown,	and	the	confidence	level	determine	the	number	338 
of	required	samples.		339 
	340 
3.3. Collection	of	(meta)information		341 
An	example	of	a	questionnaire	to	collect	(meta)information	relevant	to	evaluate	342 
the	appropriateness	of	sampling	and	to	facilitate	the	interpretation	of	results	is	can	be	343 
found	(Ort	et	al.,	2014c).	This	paper	encompasses	catchment	properties	(e.g.,	hydraulic	344 
residence	time,	population	size,	and	how	it	was	estimated),	as	well	as	details	on	sample	345 
collection	and	handling.	346 
	347 
3.4. Stability	of	IDs	biomarkers	in	the	samples	under	storage	conditions	348 
It	is	often	not	possible	to	immediately	analyse	samples	for	the	presence	of	IDBs.	349 
It	is,	therefore,	necessary	to	store	wastewater	samples	until	analysis	under	conditions	350 
that	 avoid	 transformation	of	 the	analytes,	because	biotransformation	during	 storage	351 
would	lead	to	false	interpretations	of	WBE	data,	even	if	analytical	methods	are	accurate.	352 
For	 most	 IDBs,	 experiments	 have	 been	 performed	 to	 evaluate	 stability	 for	353 
different	 storage	 conditions,	 including	 various	 temperatures,	 pH	 values,	 and	354 
preservation	 agent	 additions,	 and	 for	 different	 time	 frames	 (reviewed	 in	 detail	 by	355 
(McCall	et	al.,	2016).	Storage	of	wastewater	samples	at	-20	°C	ensures	stability	of	most	356 
IDBs	for	at	least	3	weeks.	For	some	IDBs	(i.e.,	the	amphetamine-type	stimulants	and	11-357 
nor-9-carboxy-delta-9-tetrahydrocannabinol	 (THC-COOH)),	experiments	have	revealed	358 
that	they	are	even	stable	at	-20	°C	for	more	than	15	weeks	(McCall	et	al.,	2016).	Stability	359 
is	ensured	for	only	several	days	at	4	°C,	whereas	other	IDBs	(e.g.,	cocaine)	are	within	360 
several	hours	transformed	at	this	temperature	(McCall	et	al.,	2016).		361 
Acidification	 of	 the	 samples	 increases	 stability	 of	 the	 majority	 of	 IDBs,	 but	362 
significantly	 enhances	 biotransformation	 of	 THC-COOH.	 Because	 multi-analyte	363 
determinations	are	often	applied	in	WBE	studies,	it	is,	therefore,	not	advisable	to	acidify	364 
the	samples	before	storage.	The	effect	of	the	addition	of	preservation	agents	such	as	365 
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sodium	metabisulfite	(Na2S2O5)	has	also	been	studied,	and	revealed	higher	stability	for	366 
cocaine	and	its	metabolite	benzoylecgonine	(McCall	et	al.,	2016).	However,	for	the	other	367 
IDBs,	more	experiments	need	to	be	performed	in	order	to	evaluate	the	efficacy	to	add	368 
preservation	agents	to	wastewater	samples	for	storage	purposes.	369 
	370 
3.5. Sample	treatment	371 
In	order	to	remove	solid	particles	from	the	wastewater	samples,	two	strategies	372 
can	be	followed:	(i)	a	filtration	step	with	membrane	of	glass	fiber	filters	with	pore	sizes	373 
as	 low	as	0.1	µm,	or	 (ii)	a	centrifugation	step.	 In	addition,	because	concentrations	of	374 
most	IDBs	in	wastewater	are	in	the	ng/L-µg/L	range,	a	preconcentration	step	is	generally	375 
required	 prior	 to	 analysis	 in	 order	 to	 achieve	 the	 necessary	 quantification	 limits.	376 
However,	 some	 modern	 analytical	 instruments	 allow	 direct	 injection	 of	 filtered	 or	377 
centrifuged	 wastewater	 due	 to	 the	 high	 sensitivity	 provided	 (Berset	 et	 al.,	 2010;	378 
Bisceglia	et	al.,	2010;	Boix	et	al.,	2015;	Chiaia	et	al.,	2008;	Lai	et	al.,	2011).		379 
A	 sample-preparation	 step	 is	 commonly	 needed	 not	 only	 to	 preconcentrate	380 
analytes,	but	also	to	remove	matrix	components	that	might	interfere	with	the	analytical	381 
measurement	(e.g.,	ionization	suppression/enhancement	processes	in	LC–MS)	of	IDBs.		382 
By	far,	the	most-used	procedure	reported	in	the	literature	is	off-line	solid-phase	383 
extraction	 (SPE)	with	sample	volumes	between	50	mL	and	1000	mL	 (van	Nuijs	et	al.,	384 
2011).	Popular	SPE	sorbents	used	for	a	reproducible	extraction	of	IDBs	from	wastewater	385 
are	based	on	a	polymeric	backbone	with	reversed-phase	or	cation-exchange	properties.	386 
Some	 methods	 demonstrated	 that	 off-line	 SPE	 sample	 preparation	 could	 also	 be	387 
incorporated	in	a	fully	automated	on-line	SPE	application	that	is	directly	linked	to	the	388 
LC-MS	analysis	(Fedorova	et	al.,	2013;	Heuett	et	al.,	2015;	Postigo	et	al.,	2008).	389 
Some	 alternative	ways	 of	 sample	 preparation	 can	 be	 found	 in	 the	 literature.	390 
González-Mariño	et	al.	 (González-Mariño	et	al.,	2009)	applied	commercially	available	391 
molecular	 imprinted	 polymers	 (MIPs)	 to	 extract	 and	 concentrate	 amphetamine-type	392 
stimulants	from	wastewater,	and	reported	better	performance	of	the	MIPs	in	terms	of	393 
selectivity,	 sensitivity,	 accuracy,	 and	 precision	 compared	 to	 off-line	 SPE.	 The	 main	394 
drawbacks	 of	 this	 approach	 were	 no	 possibility	 for	 multi-class	 analysis,	 and	 higher	395 
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analysis	time	and	cost.	The	usefulness	of	solid-phase	micro	extraction	(SPME)	for	sample	396 
preparation	to	analyze	amphetamine-type	stimulants	or	THC-COOH	in	wastewater	has	397 
been	demonstrated		(Racamonde	et	al.,	2013,	2012).	SPME	is	highly	compatible	with	GC-398 
MS,	 and	 shows	 good	 performance;	 however,	 the	 main	 drawback	 was	 the	 limited	399 
applicability	to	determinate	multi-class	compounds,	which	is	desired	for	WBE	purposes.	400 
	401 
4. Applications	of	Low-Resolution	Mass	Spectrometry		402 
Low-resolution	MS	systems,	with	either	ion	trap	or	QqQ	analyzers,	are	the	most	403 
widely	 applied	 for	 the	 quantitative	 determination	 of	 IDBs	 in	 wastewater.	 These	MS	404 
systems	 typically	operate	 in	 the	MS/MS	mode,	where	one	or	more	product	 ions	are	405 
monitored	 by	 selecting	 appropriate	 precursor-to-product	 ion	 transitions	 (i.e.,	 SRM).	406 
Even	with	this	approach,	there	are	some	probabilities	that	other	compounds,	not	related	407 
to	 the	 analyte,	 can	 share	 the	 same	 transition.	 Therefore,	 at	 least	 two	 transitions	 is	408 
required	 to	 be	 monitored,	 and	 the	 presence	 of	 a	 compound	 is	 considered	 to	 be	409 
confirmed	 if	both	transitions	produce	a	chromatographic	peak	at	 the	same	retention	410 
time,	 that	 corresponds	 to	 that	 of	 the	 injection	 of	 a	 reference	 standard.	 Identity	411 
confirmation	is	of	the	utmost	importance	because	it	gives	the	required	confidence	to	412 
the	 reported	 results	 and	 reduces	 the	 likelihood	 of	 reporting	 false	 positives.	 The	413 
confirmation	of	identity	is	especially	relevant	when	analyzing	highly	contaminated	and	414 
complex	matrices	such	as	influent	wastewater	samples.	For	confirmation,	not	only	the	415 
acquisition	of	 several	 transitions	 is	 needed,	 but	 also	 the	 compliance	of	 the	 ion	 ratio	416 
between	reference	standards	and	samples.	This	important	aspect	is	discussed	in	more	417 
detail	in	section	7	“Relevant	analytical	parameters	and	quality	control”.	418 
Although	 ion-trap	 analyzers	 have	 been	 used	 in	 this	 field	 (Bones	 et	 al.,	 2007;	419 
Gheorghe	et	al.,	2008;	Martínez	Bueno	et	al.,	2011;	Postigo	et	al.,	2008),	LC-MS/MS	with	420 
QqQ	has	become	the	most-popular	technique	due	to	its	excellent	performance	in	terms	421 
of	robustness,	dynamic	range,	sensitivity,	and	selectivity.	These	characteristics,	together	422 
with	the	compatibility	of	LC-MS/MS	with	aqueous	samples	and	mostly	polar	analytes	423 
targeted	 in	WBE	studies,	allow	one	 to	notably	 simplify	 sample	 treatment.	 LC-MS/MS	424 
with	QqQ	can	nowadays	be	considered	as	the	workhorse	in	analytical	laboratories	that	425 
deal	with	WBE.	This	fact	has	also	been	illustrated	in	monitoring	studies	of	illicit	drugs	in	426 
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wastewater,	where	the	majority	of	laboratories	applied	this	technique	(Castiglioni	et	al.,	427 
2008;	Ort	et	al.,	2014c;	Thomas	et	al.,	2012).		428 
Some	of	the	early	studies,	used	only	one	transition	for	quantification	(Bartelt-429 
Hunt	 et	 al.,	 2009;	 Chiaia	 et	 al.,	 2008;	 Gheorghe	 et	 al.,	 2008;	Metcalfe	 et	 al.,	 2010).	430 
However,	 it	 is	nowadays	widely	accepted	 that	confirmation	of	analyte	 identity	 in	LC-431 
MS/MS-based	 methodologies	 requires	 a	 minimum	 of	 two	 transitions	 (European	432 
Commission,	 2002).	 Yet,	 the	 acquisition	 of	 more	 transitions	 per	 compound	 would	433 
obviously	give	more	confidence	 to	 the	confirmation	process,	and	 is	 feasible	with	 the	434 
latest	analytical	instruments	with	faster	acquisition	times	(Bijlsma	et	al.,	2014a,	2009;	435 
Boleda	et	al.,	2007).	The	limited	fragmentation	in	ESI,	frequently	with	low-abundance	436 
secondary	 and	 tertiary	 transitions,	 can	 limit	 the	 absolute	 number	 of	 useful	 MRM	437 
transitions	for	identification	in	some	particular	cases.	Nevertheless,	with	the	excellent	438 
sensitivity	 of	 the	 new	 instruments,	 the	 acquisition	 of,	 at	 least,	 two	 transitions	 is	439 
commonly	not	a	problem.	Typically	the	most-abundant	transition	 is	selected	to	favor	440 
quantification	at	low	concentrations	(quantifier,	Q),	and	the	other	ones	are	acquired	for	441 
confirmation	 (qualifier,	 q).	 At	 this	 point,	 it	 is	 also	 important	 to	 understand	 the	442 
fragmentation	pattern	of	the	analytes	under	experimental	conditions	to	allow	selection	443 
of	analyte-specific	fragments	in	order	to	minimize	potential	interferences	of	the	matrix	444 
and/or	 background	 noise.	 Hence,	 it	 might	 occur	 that	 the	 most-sensitive	 transition	445 
presents	more	matrix	interference	and/or	background	noise,	and	might	therefore	not	446 
be	the	most	appropriate	for	quantification.	As	an	example,	THC-COOH,	a	metabolite	of	447 
the	 active	 ingredient	 found	 in	 cannabis,	 was	 measured	 in	 the	 positive	 electrospray	448 
ionization	(ESI)	mode.	In	this	mode,	the	transition	m/z	345	>	327	is	occasionally	selected	449 
for	quantification	(Table	1).	However,	this	transition	corresponds	to	a	non-specific	loss	450 
of	water,	which	might	be	more	prone	to	interferences	when	analyzing	complex	matrices,	451 
such	as	wastewater	 (Pozo,	 Sancho,	 Ibáñez,	Hernández,	&	Niessen,	2006).	 This	 fact	 is	452 
demonstrated	in	Figure	2,	where	three	different	transitions	were	acquired	to	measure	453 
THC-COOH	 in	 influent	 wastewater.	 The	 transitions	 345	 >	 327	 and	 345	 >	 299,	454 
corresponding	to	losses	of	H2O	and	HCOOH,	respectively,	presented	higher	noise	than	455 
the	less-abundant,	but	more-selective,	transition	345	>	193.	These	matrix	interferences	456 
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has	also	been	observed	in	the	negative	mode;	when	a	non-specific	loss	of	CO2	(343	>	457 
299)	was	measured.	458 
 459 
 460 
 461 
Figure	2.	Selectivity	of	THC-COOH	transitions.	462 
Table	1	shows	the	quantification	(Q)	and	confirmation	(q)	transitions	used	during	463 
the	 monitoring	 campaign	 2015	 coordinated	 by	 SCORE	 to	 measure	 the	 most	 widely	464 
studied	IDBs	in	influent	wastewater	in	WBE	research.	In	general,	the	Q	transition	is,	in	465 
most	studies,	the	same	with	few	exceptions.	However,	more	differences	are	observed	466 
in	the	qualifier	transition	used	for	confirmation.		467 
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Table	1.	SRM	transitions	most	often	used	with	LC-QqQ-MS	instruments	to	determine	474 
IDBs	in	wastewater	during	the	monitoring	campaign	2015	of	SCORE	(“http://score-475 
cost.eu/”).		476 
Compound	 Q-transition		
(#Labs/#total	Labs)a	
q-transition	
(#Labs/#total	Labs)b	
Amphetamine	 136	>	91			(12/17)	 136	>	119	(10/12)	
136	>	65			(2/12)	
	 136	>	119	(5/17)	 136	>	91			(5/5)	
	 	 	
Methamphetamine	 150	>	91		(13/17)	 150	>	119	(11/13)	
150	>	65			(2/13)	
	 150	>	119	(4/17)	 150	>	91			(4/4)	
	 	 	
Methylenedioxymethamphetamine	(MDMA)	 194	>	163	(15/17)	 194	>	105	(11/15)	
194	>	135	(3/15)	
194	>	77			(1/15)	
	 194	>	135	(1/17)	 194	>	105	(1/1)	
	 194	>	133	(1/17)	 194	>	105	(1/1)	
	 	 	
Cocaine	 304	>	182	(15/16)	 304	>	82			(9/15)	
304	>	150	(2/15)	
304	>	105	(2/15)	
304	>	77			(2/15)	
	 304	>	82			(1/16)	 304	>	182	(1/1)	
	 	 	
Benzoylecgonine	 290	>	168	(17/17)	 290	>	105	(13/17)	
290	>	77			(3/17)	
290	>	82			(1/17)	
	 	 	
THC-COOH		
(+)	mode	
345	>	299	(6/10)	 345	>	245	(4/6)	
345	>	327	(1/6)	
345	>	193	(1/6)	
	 345	>	327	(2/10)	 345	>	299	(1/2)	
345	>	193	(1/2)	
	 345	>	193	(1/10)	 345	>	299	(1/1)	
	 345	>	41			(1/10)	 345	>	327	(1/1)	
THC-COOH		
(-)	mode	
343	>	299	(3/5)	 343	>	245	(2/3)	
343	>	191	(1/3)	
	 343	>	245	(2/5)	 343	>	299	(2/2)	
a			Number	of	laboratories	that	selected	the	SRM	transition	(Q)	for	quantification	/	the			477 
total	of	laboratories	that	used	LRMS	and	determine	the	IBD.	478 
b	 	Number	of	 laboratories	 that	 selected	 the	SRM	 transition	 (q)	 for	 confirmation/	 the			479 
total	of	laboratories	that	selected	the	same	Q-transition	(see	also	a)	480 
	481 
Note:	 More-detailed	 information	 regarding	 the	 analytical	 procedures	 can	 be	 found	482 
elsewhere:	(Andrés-Costa	et	al.,	2014;	Berset	et	al.,	2010;	Bijlsma	et	al.,	2014a;	Borova	483 
et	 al.,	 2014;	 Castiglioni	 et	 al.,	 2006;	 Castrignanò	 et	 al.,	 2016;	 Devault	 et	 al.,	 2014;	484 
Fedorova	et	 al.,	 2013;	Kankaanpää	et	 al.,	 2014;	Karolak	et	 al.,	 2010;	 Lai	 et	 al.,	 2011;	485 
Postigo	et	al.,	2008;	Senta	et	al.,	2013;	Tscharke	et	al.,	2015;	van	Nuijs	et	al.,	2009).	It	is	486 
noteworthy	that	not	all	analytical	methodologies	used	during	the	monitoring	campaign	487 
were	published.	488 
	489 
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The	Q-transitions	selected	for	cocaine	and	its	metabolite	benzoylecgonine	(BE)	490 
are	in	practically	all	cases	304	>	182	and	290	>	168,	respectively.	Both	correspond	to	the	491 
neutral	loss	of	benzoic	acid,	specific	for	cocaine	and	its	metabolites	(Bijlsma	et	al.,	2011;	492 
Castiglioni	et	al.,	2008).	In	relation	to	the	q-transition,	some	differences	were	observed,	493 
but	304	>	82	and	290	>	105	were	most	frequently	selected.	The	Q-	and	q-transitions	for	494 
amphetamine	are	in	most	cases	136	>	91	and	136	>	119,	and	for	methamphetamine,	495 
150	>	91	and	150	>	119,	respectively.	More	variation	occurs	in	the	selection	of	transitions	496 
for	MDMA,	although	most	laboratories	use	194	>	163	for	quantification.		497 
THC-COOH	 has	 been	 measured	 in	 the	 negative-	 and	 positive-ESI	 modes.	498 
Obviously,	 different	 transitions/ions	 are	 selected	 in	 each	 case.	 The	 determination	 of	499 
THC-COOH	 is	 more	 problematic	 than	 other	 drugs	 investigated.	 The	 use	 of	 different	500 
ionization	modes,	the	poorer	sensitivity	for	this	compound,	and	the	matrix	interferences	501 
that	affect	LC–MS/MS	analysis	make	its	determination	more	troublesome	(Bijlsma	et	al.,	502 
2014b;	Ort	et	al.,	2014c;	Vazquez-Roig	et	al.,	2013).	Moreover,	other	non-instrumental	503 
factors,	such	as	possible	sorption	to	solids	(Harman	et	al.,	2011),	in-sewer	and	in-sample	504 
stability	(McCall	et	al.,	2016),	might	also	play	an	important	role	in	the	difficulty	to	get	505 
satisfactory	results	for	this	compound.	Although	some	difficulties	might	be	related	to	its	506 
different	physico-chemical	properties	(lower	polarity)	compared	with	other	illicit	drugs	507 
and	metabolites,	an	unambiguous	explanation	has	not	yet	been	found.	The	problems	508 
associated	to	the	determination	of	THC-COOH	have	been	corroborated	with	the	results	509 
of	inter-laboratory	exercises,	where	data	for	this	compound indicate	that	recoveries	of	510 
spiked	amounts	of	THC-COOH	to	wastewater	invariably	are	low;	those	data	suggest	a	511 
systematic	 underestimation	 of	 the	 true	 concentrations	 of	 THC-COOH	 in	 this	 type	 of	512 
matrix.	513 
The	 examples,	 shown	 above,	 illustrate	 that	 the	 selection	 of	 appropriate	514 
transitions	is	not	a	banal	aspect,	and	it	requires	a	detailed	study	before,	considering	not	515 
only	 the	 abundance	 of	 the	 ions	 (used	 as	 common	 criterion),	 but	 also	 specificity	 and	516 
associated	issues	such	as	background	noise.	517 
	518 
5. Applications	of	High-Resolution	Mass	Spectrometry		519 
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HRMS	 is	 a	 powerful	 technique	 with	 many	 different	 applications	 in	 the	520 
investigation	of	IDBs	in	wastewater,	from	the	screening	of	large	number	of	compounds,	521 
the	 elucidation	 of	 unknowns,	 the	 identification	 of	 new	 metabolites	 and	522 
degradation/transformation	products	(TPs),	to	quantification	of	target	analytes	at	low	523 
concentrations.	Several	reviews	have	been	published	on	the	use	of	HRMS	to	determine	524 
of	 licit	 and	 illicit	 drugs	 in	 environmental	 analysis,	 and	 are	 recommended	 for	 those	525 
researchers	 interested	 in	 this	 field	 (Farré	 et	 al.,	 2012;	Hernández	 et	 al.,	 2014,	 2012;	526 
Kaufmann,	2014;	Petrovic	et	al.,	2010;	Vazquez-Roig	et	al.,	2013;	Wong	and	MacLeod,	527 
2009).	528 
	529 
5.1. Wide-scope	screening	530 
HRMS	allows	the	efficient	screening	of	a	large	variety	of	compounds,	including	531 
IDBs,	 in	 wastewater.	 Its	 potential	 comes	 from	 the	 acquisition	 of	 accurate-mass	 full-532 
spectrum	data	(Kaufmann	et	al.,	2010).	These	data	allow	one	to	screen	of	compounds	in	533 
a	post-target	way	without	the	need	to	pre-select	the	analytes	for	method	development,	534 
as	 stated	 in	previous	 sections.	 Furthermore,	 the	presence	of	 compounds	 initially	not	535 
considered,	such	as	new	substances	and	metabolites/TPs,	can	be	also	investigated	from	536 
data	acquired	in	a	retrospective	way	without	the	need	for	additional	analysis	(Bijlsma	et	537 
al.,	 2013b;	 Hernández	 et	 al.,	 2011a).	 This	 ability	 is	 advantageous,	 because	 in	 some	538 
occasions,	samples	might	already	have	been	discarded	or	the	analytes	are	degraded,	so	539 
additional	 sample	 injections	might	not	be	possible.	 In	 this	way,	 the	screening	can	be	540 
further	widened	by	reprocessing	raw	data	without	the	need	to	perform	new	analysis.		541 
The	 most-used	 HRMS	 analyzers	 are	 undoubtedly	 TOF	 and	 Orbitrap.	 Both	542 
instruments	can	be	efficiently	coupled	with	LC,	although	TOF	MS	has	the	advantage	of	543 
easy	 coupling	 with	 ultra-high	 performance	 liquid	 chromatography	 (UHPLC).	 On	 the	544 
contrary,	restrictions	due	to	the	lower	scan	speed	can	limit	the	applicability	of	coupling	545 
an	Orbitrap	with	 UHPLC	 (Hernández	 et	 al.,	 2014).	 As	 a	 consequence	 of	 the	 intrinsic	546 
characteristics	 of	 these	 analyzers,	 the	 use	 of	 LC-HRMS	 enables	 screening	 for	 a	 large	547 
number	of	IDBs	at	satisfactory	sensitivity	within	one	analysis.	Obviously,	the	restrictions	548 
derived	 from	 the	 chromatographic	 and	 ionization	 processes	 and	 from	 sample	 pre-549 
treatment	have	to	be	taken	into	account	in	a	search	for	contaminants.	TOF	analyzers	550 
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have	been	widely	used	to	screen	licit	and	illicit	drugs,	and	their	potential	has	been	well-551 
documented	 (Hernández	 et	 al.,	 2014,	 2011a).	Mass	 resolution	 typically	 ranges	 from	552 
20,000	up	to	recently	80,000	FWHM,	whereas	mass	accuracy	<	2	ppm	and	quantitative	553 
linear	ranges	start	to	become	usual.	Following	the	invention	by	Makarov	(Hardman	and	554 
Makarov,	2003;	Hu	et	al.,	2005;	Makarov	et	al.,	2006),	the	Orbitrap	has	gained	popularity	555 
in	the	investigation	of	emerging	contaminants	(de	Voogt	et	al.,	2011;	Fedorova	et	al.,	556 
2013).	 An	 Orbitrap	 possesses	 high	 mass	 resolution	 (>100,000	 FWHM),	 high	 mass	557 
accuracy	(<5	ppm)	and	acceptable	dynamic	range	(5·103).	The	newest	instruments	can	558 
reach	up	to	450,000	FWHM	at	m/z	200	and	sub-ppm	mass	accuracy.	However,	the	main	559 
drawback	is	its	scanning	speed,	which	is	inverse	to	mass	resolution.	Thus,	a	compromise	560 
between	achievable	resolution	and	adequate	chromatography	must	be	found	(Kellmann	561 
et	al.,	2009;	Makarov	and	Scigelova,	2010).	562 
Hybrid	 configurations	 increase	 the	 potential	 of	 these	 analyzers	 for	 screening	563 
purposes.	The	most-common	are	Q-TOF	and	LIT-Orbitrap,	although	other	possibilities	564 
exist,	 such	 as	 IT-TOF	 and	 Q-Orbitrap.	 These	 hybrid	 instruments	 provide	 relevant	565 
structural	 information	 by	 obtaining	 accurate-mass	 product-ion	 spectra	 after	MS/MS	566 
experiments.	 Information	obtained	with	MS/MS	 is	 highly	 useful	 to	 confirm	potential	567 
positives	revealed	by,	for	example,	HRMS	or	QqQ	analysis,	and	to	elucidate	structures	568 
of	unknowns	or	suspect	compounds.	However,	the	pre-selection	of	the	precursor	ion	is	569 
required	 for	MS/MS	 product-ion	 generation,	 and,	 therefore,	 a	 second	 injection	 is	 in	570 
principle	needed.	 In	order	 to	overcome	these	 limitations,	product-ion	spectra	can	be	571 
collected	with	data-dependent	acquisition	 (DDA).	 In	 this	mode,	 the	 first	 scan	usually	572 
works	as	the	survey	scan,	where	data	are	processed	‘on-the-fly’	to	search	for	potential	573 
compounds	of	interest	based	on	predefined	selection	criteria;	e.g.,	intensity	threshold	574 
or	a	suspect	inclusion	list.	If	the	selection	criteria	are	met	or	the	included	ion	is	observed,	575 
then	a	second	MS/MS	scan	(data-dependent)	is	performed.	The	major	advantage	of	this	576 
approach	 is	 the	collection	of	“clean”	structural	 information	 in	 just	one	 injection.	The	577 
main	limitations	are	the	intensity	threshold	itself,	as	well	as	the	size	of	the	inclusion	list	578 
(number	of	 suspects	 searched);	both	can	negatively	affect	 the	achievable	duty	cycle.	579 
Hence,	a	decrease	in	the	number	of	data	points	(i.e.,	the	number	of	scans),	affects	the	580 
detectability	of	chromatographic	peaks.		581 
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Advantageously,	most	current	instruments	also	allow	the	acquisition	of	full-scan	582 
spectra	 at	 different	 collision	 energies	 in	 just	 one	 injection.	 As	 a	 function	 of	 the	583 
instrument	and/or	manufacturer,	this	operation	mode	for	the	QTOF	analyzer	is	known	584 
as	MSE	(Castro-Perez	et	al.,	2002;	Díaz	et	al.,	2011;	Hernández	et	al.,	2011a;	Plumb	et	al.,	585 
2006)	in	the	case	of	Waters,	broadband	collision-induced	dissociation	(bbCID)	(Dasenaki	586 
et	al.,	2015)	in	the	case	of	Bruker,	or	all-ions	MS/MS	(Kinyua	et	al.,	2015)	in	the	case	of	587 
Agilent.	Likewise	for	Q-Orbitrap	instruments	from	Thermo,	this	type	of	acquisition	is	also	588 
possible,	and	known	as	All	Ion	Fragmentation	(AIF)	(Berendsen	et	al.,	2015;	Coscollà	et	589 
al.,	2014),	or	variable	Data-Independent	Analysis	(vDIA)	(Zomer	and	Mol,	2015).	These	590 
approaches	are	possible	thanks	to	the	availability	of	collision	gas	inside	the	collision	cell	591 
of	 the	 hybrid	 instruments.	 With	 the	 application	 of	 low	 energy	 in	 the	 collision	 cell,	592 
fragmentation	is	minimized,	and	the	information	obtained	corresponds	normally	to	the	593 
parent	 molecule	 ((de)protonated	 and/or	 adducts	 in	 some	 cases).	 At	 high	 collision	594 
energy,	fragmentation	of	the	molecule	is	favored.	In	addition,	the	high-energy	function	595 
provides	not	only	 fragmentation	spectra	 similar	 to	MS/MS	experiments,	but	also	 the	596 
isotopic	pattern	of	the	fragments,	and	it	conserves	adduct	and/or	dimer	information	as	597 
the	 quadrupole	 works	 as	 an	 ion	 guide.	 In	 this	 way,	 (de)protonated	 molecule	 and	598 
fragment	ion	data	collection	are	both	enabled	in	a	single	acquisition	without	the	need	599 
to	select	the	precursor	ion;	therefore,	not	affecting	negatively	the	duty	cycle.		600 
One	of	the	main	difficulties	in	wide-scope	screening	is	to	ensure	that	the	method	601 
can	detect	and	identify	all	compounds	included	in	the	target	list.	Reference	standards	602 
are	 obviously	 required	 for	 a	 final	 confirmation	 of	 the	 identity,	 but	 also	 needed	 to	603 
perform	method	validation.	Qualitative	validation	of	the	screening	is	a	key	aspect,	but	604 
a	laborious	and	time-consuming	task.	The	objective	is	to	ensure	that	the	method	detects	605 
a	given	compound	at	an	established	minimum	concentration;	therefore,	the	screening	606 
detection	limit	(SDL)	is	the	main	parameter	evaluated.	To	this	aim,	water	samples	spiked	607 
at	 different	 levels	 need	 to	 be	 tested	 to	 establish	 the	 SDL	 as	 the	 lowest	 analyte	608 
concentration	tested	that	can	be	detected	(wiht	the	most	abundant	ion;	i.e.,	normally	609 
the	(de)protonated	molecule).	In	absence	of	guidelines	in	the	environmental	field,	the	610 
approach	used	in	other	fields,	such	as	pesticide	residue	analysis	(SANCO,	2013)	or	doping	611 
control	 analysis	 (Pozo,	 Van	 Eenoo,	 Deventer,	 &	 Delbeke,	 2007)	 can	 be	 adopted.	 To	612 
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accept	 the	 empirical	 value	 of	 SDL,	 it	 is	 necessary	 to	 have	 at	 least	 95%	 of	 positive	613 
detections	 in	 the	 spiked	 samples	 tested.	 Another	 key	 parameter	 is	 the	 limit	 of	614 
identification;	 i.e.,	 the	 lowest	 concentration	 tested	 for	 which	 the	 compound	 can	 be	615 
detected	(only	one	ion)	and	identified	(at	least	two	accurate-mass	ions,	with	acceptable	616 
mass	errors).	For	identification,	other	parameters	have	to	be	also	considered,	such	as	617 
retention	time	and	ion-ratios	(see	below).	618 
Qualitative	validation	is	normally	performed	with	selected	compounds	from	the	619 
target	 list	 that	 are	 taken	 as	 a	model,	 due	 to	 the	 extreme	 difficulties	 to	 validate	 the	620 
method	for	the	huge	number	of	compounds	that	might	be	included	in	the	target	list.	621 
Once	 the	methodology	 is	 validated,	 the	 screening	 is	 applied	 to	 sample	 analysis.	 The	622 
occurrence	 of	 false	 positives	 is	 drastically	minimized	 if	 strict	 criteria	 are	 applied	 for	623 
identification	on	the	basis	of	the	accurate-mass	data;	however,	one	cannot	ignore	the	624 
possibility	of	false	negatives	for	those	compounds	that	were	not	previously	validated.	625 
Although	the	qualitative	potential	of	HRMS	is	evident,	quantitative	applications	626 
have	been	more	limited	until	now,	mainly	because	HRMS	analyzers	typically	show	lower	627 
sensitivity	 and	 narrower	 dynamic	 range	 than	QqQ	 instruments	 that	 operate	 in	 SRM	628 
mode.	Thus,	most	research	until	now	has	been	focused	on	identification	and	elucidation	629 
purposes.	 However,	 Orbitrap	 and	 the	 latest	 TOF	 instruments	 show	 improved	630 
performance	to	prompt	their	use	also	for	quantification	of	IDBs	in	wastewater	(Bijlsma	631 
et	al.,	2013b;	González-Mariño	et	al.,	2012).		632 
The	strategy	used	for	HRMS	screening	strongly	depends	on	the	availability	of	633 
reference	 standards,	 as	 described	 previously.	 Nevertheless,	 when	 dealing	 with	634 
thousands	of	compounds,	it	is	almost	impossible	to	have	all	reference	standards	in	the	635 
laboratory.	One	of	 the	main	benefits	with	HRMS	 is	 that	 reference	 standards	are	not	636 
strictly	 required	 in	 a	 first	 step	 of	 the	 process,	 because	 a	 tentative	 identification	 of	637 
suspect	compounds	can	be	made	on	the	basis	of	the	obtained	information.	Obviously,	638 
reference	 standards	 highly	 facilitate	 the	 analytical	 task	 in	 the	 screening,	 and	 are	639 
required	 for	ultimate	and	unambiguous	 confirmation	 (Fig.	 3);	 however,	 they	may	be	640 
acquired	only	in	a	final	stage	when	solid	well-founded	evidence	exists	on	the	presence	641 
of	 the	 compound	 in	 the	 sample.	 In	 this	way,	 laboratories	do	not	need	 to	acquire	all	642 
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reference	standards	before	analysis,	with	the	subsequent	problems	of	availability	(e.g.,	643 
TPs),	costs,	and	expiry	dates	(Ibáñez	et	al.,	2014).	644 
	645 
	646 
Figure	3.	(Post)-target	screening	strategy.	647 
	648 
In	 the	 absence	 of	 reference	 standards,	 HRMS	 data	 might	 be	 sufficient	 for	 a	649 
tentative	identification	(Fig.3).	An	example,	identification	of	2-ethylidene-1,5-dimethyl-650 
3,3-diphenylpyrrolidine	(EDDP),	a	metabolite	of	methadone,	in	wastewater	by	LC-QTOF	651 
MS,	is	shown	in	Figure	4.	By	combining	the	information	obtained	in	the	low-energy	(LE)	652 
function	 on	 the	 protonated	 molecule	 and	 in	 the	 high-energy	 (HE)	 function	 on	 the	653 
fragment	 ions,	 tentative	 identification	 of	 this	 metabolite	 was	 feasible	 without	 any	654 
reference	 standard.	 The	 use	 of	 UHPLC	 also	 facilitated	 the	 assignment	 of	 the	655 
chromatographic	 peaks	 that	 corresponded	 to	 this	 compound	 (note	 that	 some	 ions	656 
present	in	the	HE	spectra	did	not	correspond	to	EDDP;	marked	as	x	in	the	figure).		657 
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	658 
Figure	 4.	 Tentative	 identification	 of	 EDDP,	 a	 methadone	 metabolite.	 A)	 LE	 mass	659 
spectrum	 (bottom)	HE	mass	 spectrum	 (top).	B)	XICs	of	 the	protonated	molecule	and	660 
several	fragment	ions	(X	indicates	that	the	fragment	ion	is	not	related	to	EDDP).	661 
	662 
Successful	 identification	 depends	 on	 the	 quality	 of	 the	 information	 provided	663 
(e.g.,	more	than	one	accurate-mass	is	required,	low	mass	errors	give	more	confidence	664 
to	 the	 process)	 and	 on	 the	 knowledge	 of	mass	 spectrometry	 fragmentation	 rules	 to	665 
properly	justify	the	fragment	ions	observed.	Previous	data	reported	in	the	literature	on	666 
fragment	ions	(in	nominal	and	accurate	mass),	which	can	also	be	available	in	databases	667 
such	as	MassBank	 (Horai	et	al.,	2010;	 “http://www.massbank.jp/”),	 are	useful	 to	 the	668 
analyst.	 Another	 interesting	 tool	 is	 retention-time	prediction,	which	helps	 to	 discard	669 
potential	false	positives	and	to	focus	the	elucidation	process	on	only	those	peaks	that	670 
fit	 the	predicted	tR.	These	tR	predictors	are	based	on	quantitative	structure-retention	671 
relationships	(QSRRs)	that	vary	from	very	simple,	which	incorporate	a	single	descriptor	672 
(Bade	et	al.,	2015b;	Kern	et	al.,	2009),	to	more	complex,	which	use	a	large	number	of	673 
descriptors	(Bade	et	al.,	2015a;	Barron	and	McEneff,	2016;	Gago-Ferrero	et	al.,	2015;	674 
Miller	et	al.,	2013;	Munro	et	al.,	2015);	however,	all	of	these	predictors	are	based	on	a	675 
EDDP
C20H24N+
-0.3 mDa
C18H19N+·
0.0 mDa
C17H16N+
- 0.2 mDa
C13H16N+
- 0.1 mDa
- 0.3 NH2
NH2
NH
mDa
C6H12N+
NH
278.1903 LE
249.1512
234.1277
186.1277
150.0918
108.0811
98.0964
XIC
HE
A B
X
X
XX
NH
28 
 
single	column,	commonly	a	reversed	phase	(C18)	column.	A	direct-mapping	technique	676 
(PredRet)	able	to	predict	retention	times	across	different	chromatographic	systems	has	677 
also	 recently	 been	 developed	 (Stanstrup	 et	 al.,	 2015),	 but	 is	 limited	 to	 compounds	678 
having	to	be	within	the	PredRet	database.	Although	this	area	is	rapidly	advancing,	the	679 
principal	 limitation	 is	 the	 use	 of	 a	 single	 column	 for	 most	 predictions,	 with	 further	680 
optimization	needed	for	a	truly	transferable	prediction	technique.	681 
One	 of	 the	 issues	 that	 still	 remains	 without	 broad	 consensus	 is	 the	 criteria	682 
applied	for	confident	identity	identification/confirmation.	It	is	clear	that	a	combination	683 
of	parameters	is	required	for	this	aim,	including	retention	time	and	MS	data.	Accurate-684 
mass	measurements	 give	more	 confidence	 for	 a	 reliable	 identification	 than	 nominal	685 
mass	data,	and	this	factor	is	recognized	in	several	guidelines,	which,	for	example,	give	686 
more	identification	points	to	HRMS	ions	than	LRMS	ions	(European	Commission,	2002).	687 
In	 addition,	 the	 ion	 intensity	 ratio	 is	 commonly	 used	 as	 a	 key	 parameter	 in	 the	688 
identification	process.	 It	 is	widely	 accepted	 that	 at	 least	 two	accurate-mass	 ions	 are	689 
required	for	a	confident	identification	with	HRMS.	However,	two	main	issues	need	to	be	690 
considered:	1)	what	 is	the	acceptable	mass	error?	2)	what	 is	the	maximum	deviation	691 
acceptable	in	the	ion	ratio?	Moreover,	another	parameter	helpful	in	the	process	is	the	692 
isotopic	distribution,	especially	when	abundant	isotope	ions	such	as	chlorine,	sulphur,	693 
or	bromine	are	present.	Several	situations	might	occur	that	lead	to	different	degrees	of	694 
confidence	in	identification.	For	example,	Schymanski	et	al.	(Schymanski	et	al.,	2014a)	695 
propose	up	to	5	levels	of	confidence	in	a	non-target	analysis.	These	levels	range	from	696 
only	 exact	 mass	 to	 unequivocal	 molecular	 formula,	 and	 then	 tentative	 candidate(s)	697 
followed	by	probable	structure	to	a	fully	confirmed	structure	with	a	reference	standard.		698 
Figure	5	summarizes	the	key	parameters	in	the	detection	and	identification	of	a	699 
compound	with	HRMS.	As	 shown	 in	 this	 figure,	 different	 scenarios	might	 occur	 as	 a	700 
function	 on	 the	 information	 provided,	 and	 on	 the	 availability	 of	 reference	 standard	701 
(Bade	et	al.,	2015c;	Hernández	et	al.,	2015a;	Nácher-Mestre	et	al.,	2016).	702 
	703 
	704 
	705 
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	706 
Figure	 5.	 Detection	 and	 identification	 criteria	 in	 screening	 of	 illicit	 drugs	with	HRMS	707 
(modified	from	(Nácher-Mestre	et	al.,	2016)).	708 
	709 
When	 a	 reference	 standard	 is	 available,	 compounds	 can	 be	 detected	 or	710 
identified.	 Detection	 is	 considered	 satisfactory	 when	 the	 most-abundant	 ion	 (Q),	711 
commonly	the	 (de)protonated	molecule,	 is	 found	at	 the	expected	tR	 (±	0.1	min,)	and	712 
mass	error	<	5	ppm	(SANTE/11945,	2015).	Another	likely	situation	for	detection	is	to	find	713 
two	representative	ions	(i.e.,	the	most-abundant	ion	(Q)	and	a	fragment/adduct	ions(q)	714 
at	the	expected	tR),	but	with	mass	errors	between	5-20	ppm.	The	latter	situation	seems	715 
to	occur	when	the	signal	intensity	is	low	(favored	at	low	analyte	concentrations).	In	that	716 
case,	 an	 additional	 effort	 is	 recommended	 to	 investigate	 more	 accurate-mass	 ions	717 
and/or	repeat	sample	injection. 	Identification	is	based	on	the	presence	of	at	least	two	718 
representative	ions	(Q,	q)	at	the	expected	tR	with	mass	errors	<	5	ppm.	Additionally,	q/Q	719 
ratios	 should	 fit	 with	 those	 for	 reference	 standards	 within	 tolerance	 limits	720 
(SANTE/11945,	2015).	Identification	under	these	conditions	is	highly	reliable	and	can	be	721 
considered	as	the	ideal	situation.	722 
When	the	reference	standard	is	not	available, a	tentative	identification	can	be	723 
made	when	an	expected	 ion	with	mass	error	<	5	ppm	 is	observed,	 together	with	 its	724 
Screening with HRMS, key parameters
Retention time (Rt)
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Isotope pattern (Cl, Br…)
• Expected ion (Q), mass error < 5 ppm)
• Compatible isotope pattern (Cl, Br...)
• One or more fragment ions (q), 
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• Rt agreement 
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characteristic	isotopic	pattern.	Subsequently,	the	fragment	ions	should	be	evaluated	by	725 
comparing	the	data	with,	e.g.,	data	reported	in	the	literature	or	justified	by	the	accurate-726 
mass	 fragments	 taking	 into	 account	 the	 structure	 of	 the	 molecule.	 However,	 for	727 
structure	confirmation,	injection	of	the	reference	standard	is	eventually	required.	728 
	729 
5.2. Non-target	analysis	730 
Full-spectrum	 accurate-mass	 acquisition	 provided	 with	 HRMS	 also	 opens	 the	731 
possibility	to	investigate	non-target	compounds	in	water	(Díaz	et	al.,	2012;	Hernández	732 
et	al.,	2011b;	Hug	et	al.,	2014;	Ibáñez	et	al.,	2005;	Krauss	et	al.,	2010;	Schymanski	et	al.,	733 
2015).	A	true	“unbiased”	non-target	screening,	without	any	a	priori	information	on	the	734 
compounds	to	be	detected,	is	an	analytical	challenge.	This	process	needs	expertise,	and	735 
is	complex	and	time-consuming.	The	main	difficulties	associated	with	this	process	when	736 
applied	 to	 environmental	 or	wastewater	 samples	 come	 from:	 (i)	 the	 complexity	 and	737 
unknown	composition	of	the	sample	that	is	investigated,	(ii)	the	presence	of	many	peaks	738 
in	 the	 total	 ion	 chromatogram	with	 the	most-abundant	 corresponding	 commonly	 to	739 
compounds	other	than	the	analytes,	and,	(iii)	the	low	analyte	concentrations.	Thus,	the	740 
main	problem	is	to	prioritize	the	most	“relevant”	chromatographic	peaks	in	the	sample,	741 
because	the	majority	will	not	be	associated	to	drugs,	in	order	to	focus	the	subsequent	742 
elucidation	 process	 on	 those	 compounds.	 From	 the	 HRMS	 information,	 a	 complex	743 
process	 has	 to	 be	 applied	 	 that	 establishes	 the	 empirical	 formula	 of	 the	 unknown	744 
compound,	searches	chemical	databases	for	potential	candidates,	and	finally	assigns	the	745 
chemical	structure	of	the	discovered	compound.	746 
In	a	 true	non-target	analysis,	 the	maximum	number	of	 compounds	 from	very	747 
different	 physico-chemical	 characteristics	 should	 be	 investigated.	 Therefore,	 a	748 
combination	 of	 GC-HRMS	 and	 LC-HRMS	 seems	 to	 be	 the	 most-appropriate	 way	 to	749 
achieve	this	aim.	Due	to	the	complementarity	of	these	two	techniques	this	approach	750 
can	be	 seen	as	 the	most-comprehensive	 to	advance	 towards	 the	desired	 “universal”	751 
screening	(Hernández	et	al.,	2015b).	Obviously,	some	“difficult”	compounds	would	not	752 
likely	 be	 included	 in	 a	 wide-scope	 screening.	 For	 example,	 very	 polar/ionic	 analytes	753 
would	require	specific	chromatographic	separation	(e.g.,	HILIC).	Thus,	a	combination	of	754 
C18	and	HILIC	chromatographic	columns	would	render	a	wider	scope	for	LC-amenable	755 
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compounds.	It	must	be	taken	also	into	account	that	universality	of	the	screening	should	756 
not	refer	only	to	the	techniques	of	measurement	but	also	to	the	sample	treatment.	From	757 
this	point	of	view,	a	generic	extraction,	or	even	better,	direct	analysis	of	samples	into	758 
the	MS	 system,	would	 be	 the	 best	 option	 to	 avoid	 compound	 losses	 during	 sample	759 
manipulation.		760 
Because	 no	 pre-selection	 of	 analytes	 is	 made	 in	 non-target	 analysis,	 the	761 
compounds	discovered	in	water	samples	might	belong	to	the	illicit	drugs	group,	but	also	762 
to	any	other	family	of	organic	contaminants	or	their	metabolites.	The	fact	that	most	IDBs	763 
are	of	medium	to	high	polarity	makes	LC-HRMS	the	most-attractive	approach	for	their	764 
potential	identification.	However,	the	absence	of	standardized	mass	spectral	libraries	in	765 
LC-MS	is	an	additional	difficulty	in	non-target	analysis.	Advances	in	the	creation	of	mass	766 
spectra	 libraries	 for	 LC-MS/MS	analysis	will	 be	of	help	 in	 the	near	 future,	but	 at	 the	767 
moment	the	analyst	does	not	count	on	the	aid	of	standardized	libraries	to	facilitate	a	768 
non-target	analysis.		769 
An	 intermediate	 situation	 between	 target	 and	 true	 non-target	 analysis	 is	 the	770 
application	of	“biased”	non-target	approaches,	where,	for	example,	the	formation	of	771 
“unknown”	metabolites/TPs	 from	 a	 given	 parent	 compound	 is	 investigated	 with	 “in	772 
vitro”	or	“in	vivo”	experiments,	degradation	laboratory	experiments,	or	in-silico	models	773 
(Reid	 et	 al.,	 2014a).	 Hence,	 the	 investigation	 is	 focused	 on	 chemically	 related	774 
compounds	(e.g.,	share	a	common	fragment,	moiety,	or	mass	defect)	or	on	compounds	775 
that	have	specific	atoms	in	their	structure	that	give	a	distinctive	isotopic	signature	(e.g.,	776 
Cl,	Br,	S).	Here,	the	number	of	chemically	meaningful	structures,	which	can	be	assigned	777 
to	an	unknown	peak,	 is	 limited	 to	 structures	 that	 show	a	close	 relationship	with	 the	778 
parent	compound	(Krauss	et	al.,	2010).	This	issue	will	briefly	be	treated	in	the	following	779 
section.	780 
	781 
5.3. Investigation	of	metabolites	and	transformation	products	782 
The	 investigation	of	metabolites	and	TPs	of	 illicit	drugs	 in	water	 samples	 is	a	783 
current	 topic	 of	 research	 (Bletsou	et	 al.,	 2015).	WBE	 is	 based	on	 the	 analysis	 of	 key	784 
biomarkers	of	drugs.	These	IDBs	can	be	the	parent	compound	and/or	the	major	urinary	785 
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metabolite(s).	For	the	most	known	and	widely	consumed	drugs,	information	on	human	786 
metabolism	is	already	available,	and	has	allowed	establishment	of	benzoylecgonine	as	787 
the	main	metabolite	 and	 IDB	 of	 cocaine,	 THC-COOH	 as	main	metabolite	 and	 IDB	 of	788 
cannabis,	or	that	methamphetamine,	amphetamine,	and	MDMA	are	mainly	excreted	as	789 
unchanged	 compounds.	 However,	 this	 information	 is	 usually	 scarce	 for	 NPS	 and,	790 
therefore,	the	main	biomarker	of	use	is	generally	not	well-established.		791 
Although	WBE	is	solely	based	on	the	measurement	of	appropriate	metabolites	792 
that	result	from	human	excretion	(commonly	the	major	and	most-stable	ones),	there	is	793 
also	a	concern	about	the	presence	of	many	other	metabolites	and	TPs	of	illicit	and	licit	794 
drugs	 in	 the	 aquatic	 environment.	 Especially,	 possible	 long-term	 (chronic)	 effects	 on	795 
organisms	and	effects	of	combined	exposure	to	multiple	compounds	is	of	concern	(van	796 
der	Aa	et	al.,	2013).	The	detection	and	identification	of	these	compounds	is	a	challenge	797 
for	environmental	analytical	chemists,	and	different	approaches	can	be	followed	to	this	798 
aim.	In	the	case	of	known	metabolites	and	TPs,	already	reported	in	the	literature,	an	799 
inclusion	list	of	target	analytes	can	be	made.	From	an	analytical	point	of	view,	they	can	800 
be	 treated	 similarly	 to	 their	 parent	 compound	 with	 the	 above-mentioned	 target	801 
methodologies.	 Furthermore,	 retrospective	 analysis	 is	 also	 feasible	 by	 reviewing	 the	802 
acquired	 MS	 data.	 For	 example,	 metabolites	 of	 drugs	 have	 been	 retrospectively	803 
investigated	in	wastewater	samples	previously	analyzed	for	parent	compounds	only.	In	804 
this	way,	several	metabolites	were	tentatively	identified	without	the	need	of	additional	805 
analysis,	 and	 illustrate	 the	 potential	 of	 HRMS	 in	 this	 field	 (Bijlsma	 et	 al.,	 2013b;	806 
Hernández	et	al.,	2011a).		807 
Regarding	unknown	metabolites	 and	TPs,	 the	use	of	 common	 fragmentation	808 
pathways	 between	 the	 parent	 compound	 and	 metabolites/TPs	 might	 discover	809 
new/unexpected	 compounds.	 In	 this	 strategy,	 a	 common	 behavior	 in	 their	810 
fragmentation	 is	 assumed.	 The	presence	of	 additional	 chromatographic	peaks	 at	 the	811 
accurate	 masses	 of	 the	 fragments	 might	 reveal	 the	 presence	 of	 analyte-related	812 
compounds.	 The	 accurate-mass	 spectra	 and	 appropriate	 study	 of	 the	 fragmentation	813 
might	finally	allow	the	(tentative)	identification	of	metabolites/TPs	(García-Reyes	et	al.,	814 
2007;	Hernández	et	al.,	2011b;	Thurman	et	al.,	2005).	This	approach	can	be	extended	815 
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based	not	only	on	the	fragmentation	pathway	of	the	parent	compound,	but	also	on	that	816 
of	metabolites/TPs	detected	in	samples	(Hernández	et	al.,	2009).	817 
A	 simpler	 approach	 is	 prediction	 of	 possible	 metabolites	 or	 TPs	 with	818 
computational	(in	silico)	prediction	tools	(Kirchmair	et	al.,	2015;	Reid	et	al.,	2014a).	Many	819 
different	 methodologies	 to	 predict	 metabolites	 or	 sites	 of	 metabolism	 have	 been	820 
reported	recently.	The	metabolic	fate	of	a	molecule	depends	on	its	chemical	reactivity	821 
towards	metabolic	processes	that	can	occur,	as	well	as	on	its	interactions	(affinity	and	822 
binding	 orientation)	 with	 the	 biotransformation	 enzymes	 involved.	 The	 prediction	823 
system	should,	therefore,	properly	be	selected	after	consideration	of	the	organism	or	824 
the	 system	 where	 metabolites/TPs	 are	 formed.	 Commercially	 available	 and	 freely	825 
accessible	programs	have	been	applied	 in	 this	prediction	 step.	Kirchmair	et	al,	2015,	826 
reviewed	ten	different	software	for	predicting	metabolites,	but	only	two	are	without	827 
costs	and	an	additional	one	is	solely	available	for	academia	(Kirchmair	et	al.,	2015).	This	828 
free-availability	is	probably	the	main	reason	that	the	University	of	Minnesota	Pathway	829 
Prediction	System	(UM-PPS:	(“http://eawag-bbd.ethz.ch/”)	is	one	of	the	most-common	830 
prediction	tools	in	suspect	metabolite/TPs	screening	(Kern	et	al.,	2009).	831 
Prediction	of	metabolites/TPs	is	followed	by	HRMS	analysis;	the	exact	mass	for	832 
each	of	the	predicted	compound	is	extracted	from	the	chromatogram	and	checked	by	a	833 
comparison	with	control	samples.	The	plausibility	of	the	chromatographic	tR,	 isotopic	834 
pattern,	and	ionization	efficiency	are	used	as	further	filters	to	narrow	down	the	number	835 
of	candidate	peaks.	The	structures	of	suspected	compounds	are	tentatively	identified	836 
based	on	the	observed	fragmentation	pattern.	837 
A	suitable	strategy	to	investigate	metabolites	and	TPs	makes	use	of	“in	vitro”	or	838 
“in	vivo”	metabolism	experiments,	and	of	laboratory	or	field-degradation	experiments	839 
under	controlled	conditions,	which	can	identify	known	and	unknown	metabolites	or	TPs	840 
of	selected	drugs,	respectively.	In	the	recent	literature,	several	examples	can	be	found	841 
that	deal	with	the	investigation	of	drug	metabolites	with	in	vitro	or	in	vivo	experiments	842 
(Holm	et	al.,	2015;	Ibañez	et	al.,	2016;	Meyer	et	al.,	2015;	Pozo	et	al.,	2014;	Takayama	843 
et	al.,	2014).	These	experiments	are	very	useful	and	allow	the	discovery	of	metabolites,	844 
which	might	 be	 expected	 and	 detected	 in	wastewater,	 and	 are,	 therefore,	 potential	845 
target	IDBs	in	future	WBE-based	studies.	The	discovery	of	metabolites	is	of	particular	846 
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relevance	for	new	drugs;	i.e.,	NPS	whose	metabolism	is	not	well	known.	Other	papers	847 
study	 the	 degradation	 of	 illicit	 drugs,	 after	 spiked	 samples	 have	 been	 subjected	 to	848 
processes,	such	as	hydrolysis,	photodegradation,	chlorination,	biodegradation,	or	any	849 
other	process	of	 interest	(Bijlsma	et	al.,	2013a;	Boix	et	al.,	2014,	2013;	Postigo	et	al.,	850 
2011).	 In	 all	 cases,	 HRMS	 plays	 a	 key	 role	 in	 the	 tentative	 identification	 of	 the	851 
compounds	formed.	Furthermore,	the	use	of	specialized	software	is	critical	for	a	rapid	852 
and	efficient	 comparison	between	 the	 full	 scan	data	 set	 from	untreated	and	 treated	853 
samples,	because	manual	inspection	of	TIC	chromatogram	to	look	for	visible	peaks	can	854 
easily	fail	in	complex	matrices	with	low	analyte	concentrations.	855 
	856 
6. Chiral	analysis	857 
The	 determination	 of	 specific	metabolic	 excretion	 products	 of	 illicit	 drugs	 in	858 
wastewater	 is	 not	 always	 possible,	 and	makes	 difficult	 the	 differentiation	 between	859 
consumption	of	drugs	and	direct	disposal	of	unused	drugs.	 In	 such	 situations,	 chiral	860 
analysis	 can	 be	 applied	 because	 most	 illicit	 drugs	 are	 chiral,	 and	 are	 subject	 to	861 
stereoselective	human	metabolism	 (Emke	et	al.,	 2014;	Evans	and	Kasprzyk-Hordern,	862 
2014).		863 
MDMA	 (3,4-methylenedioxymethamphetamine)	 and	 MDA	 (3,4-864 
methylenedioxyamphetamine)	profiling	 in	wastewater	 is	an	excellent	example	of	 the	865 
importance	of	chiral	enantioselective	analysis	to	distinguish	between	consumption	and	866 
direct	disposal	of	unused	MDMA	and	MDA.	Both	drugs	have	one	asymmetric	carbon	867 
center	and	therefore	they	can	exist	in	the	form	of	two	enantiomeric	pairs,	which	differ	868 
both	quantitatively	and	qualitatively	in	pharmacological	activity:	S(+)-enantiomers	are	869 
more	 amphetamine-like	 stimulants	 and	 R(−)-enantiomers	 are	 more	 hallucinogenic	870 
(Kasprzyk-Hordern	and	Baker,	2012a).	Both	MDMA	and	MDA	have	no	medical	usage	and	871 
are	 synthesized	 and	 abused	 in	 racemic	 forms.	 	 Their	 human	 metabolism	 is	872 
stereoselective	 and	 leads	 to	 the	 enrichment	 of	 excreted	 drugs	 with	 their	 R(−)-873 
enantiomers.	However,	if	the	presence	of	MDA	in	urine	is	due	to	MDMA	abuse	and	not	874 
direct	MDA	use,	an	enrichment	of	MDA	with	S(+)-enantiomer	takes	place	(Moore	et	al.,	875 
1996).	It	is,	therefore,	expected	that	after	consumption,	both	drugs	will	be	present	in	876 
urine	and	wastewater	enriched	with	R(-)-enantiomers.	 Indeed,	Kasprzyk-Hordern	and	877 
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Baker	(Kasprzyk-Hordern	and	Baker,	2012a)	reported,	in	a	first	study	of	this	kind,	that	878 
MDMA	was	enriched	with	the	R(-)-enantiomer	due	to	preferential	metabolism	of	S(+)-879 
MDMA	 in	 humans.	 Furthermore,	 the	 identified	 MDA	 was	 enriched	 with	 S(+)-880 
enantiomer,	to	suggest	that	its	presence	might	be	associated	with	MDMA	consumption	881 
and	its	subsequent	metabolism	into	S(+)-MDA	and	not	intentional	MDA	use	(if	the	latter	882 
were	true,	MDA	in	wastewater	would	be	enriched	with	R(-)-enantiomer).		883 
Surprisingly,	in	several	instances,	during	Europe-wide	monitoring	undertaken	by	884 
the	SCORE	group	in	2011-13	(Emke	et	al.,	2014;	Ort	et	al.,	2014c;	Thomas	et	al.,	2012),	885 
unexpectedly	high	loads	of	MDMA	were	observed.	For	example,	in	2011,	aberrantly	high	886 
mass	loads	of	MDMA	were	observed	in	the	wastewater	of	Utrecht	in	the	Netherlands.	887 
These	 loads	 highly	 deviated	 from	 the	 results	 observed	 in	 the	 previous	 monitoring	888 
campaign	 in	 2010	 (Bijlsma	 et	 al.,	 2012).	 Enantiomeric	 profiling	 as	 shown	 in	Figure	 6	889 
revealed	that	MDMA	was	racemic	(enantiomeric	fraction	(EF)	=	0.54),	which	indicated	890 
its	 direct	 disposal	 in	 the	 sewage	 system	 and	 further	 explains	 high	 loads	 of	 MDMA	891 
quantified	in	Utrecht	wastewater	during	the	sampling	week	in	2011	(average	load	was	892 
20-times	higher	than	in	2010).	In	contrast,	the	samples	from	2010	(green	line	in	Fig.	6)	893 
showed	an	average	EF	of	 0.65	 that	 corresponded	 to	excretion	profiles	 in	urine	 after	894 
consumption	of	MDMA	(Emke	et	al.,	2014).	This	direct	disposal	could	be	the	result	of	a	895 
police	 raid	 into	 an	 illegal	 production	 facility	 that	 took	 place	 two	 days	 before	 the	896 
monitoring	started	(Emke	et	al.,	2014).	The	police	estimated	that	30	kg	of	raw	MDMA	or	897 
tablets	had	been	disposed	under	the	pressure	of	the	police	raid.	898 
	Enantiomeric	profiling	of	wastewater	represents	a	powerful	tool	that	allow	to	899 
determine	if	mass	loads	of	studied	drugs	actually	originated	from	consumption,	disposal	900 
of	unused	drugs,	or	production	waste.	901 
	902 
	903 
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	904 
Figure	6.	MDMA	 loads	during	 two	 separate	weeks	 sampled	 in	2010	and	2011	 in	 the	905 
sewage	 treatment	 plant	 of	 Utrecht,	 the	 Netherlands,	 and	 their	 corresponding	906 
enantiomeric	fractions	(EF)	(Emke	et	al.,	2014).	907 
	908 
Cellobiohydrolase	 (CBH)	 is	 the	 most	 widely	 used	 stationary	 phase	 for	909 
enantiomeric	profiling	of	amphetamines	with	chiral	liquid	chromatography	coupled	with	910 
tandem	mass	spectrometry.	This	cellulase	enzyme	is	immobilized	onto	5	µm	silica	beads	911 
with	an	isoelectric	point	(pI)	of	3.9.		It	contains	multiple	chiral	centres	and	mechanisms	912 
for	ionic,	hydrophobic,	and	hydrogen	bonding.		It	has	been	successfully	applied	with	an	913 
isocratic	mobile	phase	of	H2O	with	10	%	2-propanol	and	1	mM	NH4OH,	to	amphetamine-914 
like	compounds	(Fig.	6	and	7)	(Bagnall	et	al.,	2012;	Emke	et	al.,	2014;	Kasprzyk-Hordern	915 
and	Baker,	2012a,	2012b).	There	are	several	factors	that	have	to	be	taken	into	account	916 
to	achieve	satisfactory	chiral	recognition	on	CBH.	These	are	primarily	temperature,	pH	917 
and	mobile-phase	composition.	Mobile-phase	pH	plays	a	key	role	in	chiral	recognition	918 
because	it	influences	ionization	of	both	analytes	and	CBH.	Due	to	the	isoelectric	point	of	919 
3.9,	CBH	is	negatively	charged	at	pH>pI,	so	increasing	the	mobile	phase	pH	will	facilitate	920 
ionic	interactions	with	positively	charged	analyte	(e.g.,	amphetamine	or	MDMA).	This	921 
interaction	 will	 facilitate	 longer	 retention	 times	 and	 higher	 enantioselectivity.	922 
Hydrophobic	interactions	and	hydrogen	bonding	can	be	influenced	with	mobile	phases	923 
that	contain	different	nature	and	percentage	of	organic	modifiers	and	 ionic	strength.	924 
Less	than	20%	of	organic	modifier	 is	allowed	to	avoid	denaturation	of	this	enzymatic	925 
chiral	selector.	Lower	percentages	of	organic	modifiers	lead	to	higher	retention	in	the	926 
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case	 of	 amphetamine-like	 compounds.	 Isopropanol,	 methanol,	 or	 acetonitrile	 are	927 
usually	used	as	organic	modifiers.	They	are	characterized	by	different	elution	strengths;	928 
e.g.,	methanol	 has	 a	 lower	 elution	 strength	 than	 isopropranol.	 Other	 factors,	 which	929 
should	 be	 considered	 are	 (Camacho-Muñoz	 et	 al.,	 2016):	 (i)	 correct	 sampling	 and	930 
sample-preparation	 protocols	 that	 do	 not	 introduce	 stereoselectivity	 (e.g.,	microbial	931 
metabolic	degradation	of	analytes	might	lead	to	incorrect	estimation	of	enantiomeric	932 
fractions,	 or	 use	of	 charged	eluting	 agents	 during	 SPE	 (e.g.,	methanol	modified	with	933 
ammonium	hydroxide)	might	lead	to	loss	of	chiral	recognition	in	the	CBH	column),	and	934 
(ii)	elimination	of	matrix	effects	(via	robust	sample	preparation	approaches	and	use	of	935 
deuterated	or	13C-labelled	internal	standards).	936 
Enantiomeric	profiling	has	been	used	in	WBE	as	a	complementary	tool	alongside	937 
non-chiral	multi-residue	methods	 that	 use	 reversed	 phase	 (C18)	 stationary	materials.	938 
This	additional	analysis	required	an	ad	hoc	sample	preparation,	which	meant	a	higher	939 
quantity	 of	 sample,	 and	 a	 more	 time-consuming	 and	 less-cost	 effective	 analysis.	 A	940 
recently	developed	multi-residue	method	combined	chiral	recognition	capability	of	the	941 
CBH-based	stationary	materials	with	multi-residue	separation	potential	of	the	C18-based	942 
materials.	The	methodology	enabled	detection	and	quantification	of	all	targeted	(chiral	943 
and	non-chiral)	human	biomarkers	in	wastewater	along	with	satisfactory	enantiomeric	944 
separations	of	18	analytes	and	a	unique	single	sample-preparation	step	(Castrignanò	et	945 
al.,	2016).	946 
	947 
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	948 
Figure	7.	Mass	chromatograms	show	chiral	drugs:	amphetamine	(AMPH),	MDMA,	MDA	949 
and	methamphetamine	 (METH)	 in	wastewater	obtained	with	CBH	column	and	HPLC-950 
QqQ	MS	(modified	from	(Kasprzyk-Hordern	and	Baker,	2012b)). 951 
 952 
7. Relevant	analytical	parameters	and	quality	control	953 
The	use	of	advanced	analytical	techniques	and	the	expertise	of	the	analyst	are	954 
essential	 to	 obtain	 accurate	 quantitative	 data	 for	 IDBs	 in	 wastewater	 samples.	 In	955 
addition,	appropriate	measures	for	quality	control	are	required	to	obtain	reliable	data.		956 
 1 
 2
																S(+)-MDA			
									R(-)-MDA	
R(-)-MDMA									
									S(+)-MDMA	
																					S(+)-METH		
	R(-)-METH					
													R(-)-AMPH						
																						S(+)-AMPH	
39 
 
Obviously,	prior	to	its	application,	the	analytical	methodology	needs	to	be	fully	957 
validated	for	all	analytes	in	terms	of	linearity,	trueness/accuracy	(evaluated	by	means	958 
of	recovery	experiments)	and	precision	(as	repeatability	RSD),	selectivity/specificity,	and	959 
limits	of	detection	(LOD)	and	quantification	(LOQ).	One	of	the	main	drawbacks	in	this	960 
field	is	the	lack	of	guidelines	specifically	directed	towards	analysis	of	IDBs	in	wastewater.	961 
In	 absence	 of	 such	 guidelines,	 recommendations	 in	 other	 fields,	 such	 as	 pesticide	962 
residue	 analysis	 (SANCO,	 2013;	 SANTE/11945,	 2015),	 residues	 in	 products	 of	 animal	963 
origin	(European	Commission,	2002)	bioanalytical	methods	(EMA,	2012),	or	clear	water	964 
act	programs	(EPA,	2007)		can	be	used	as	guidelines.		965 
Commonly,	a	minimum	of	5	replicates	are	required	to	check	the	accuracy	and	966 
precision	at	the	targeted	LOQ,	and	at	least	one	other	higher	level,	for	example,	10	times	967 
the	 targeted	 LOQ.	 A	 quantitative	 analytical	 method	 should	 be	 demonstrated	 at	 the	968 
initial	validation,	but	also	later	with	sample	batches	to	perform	quality	controls	(QCs)	969 
that	provide	acceptable	recovery	at	each	spiking	level	and	for	each	analyte.	Acceptable	970 
mean	 recoveries	 for	 IDBs	 in	wastewater	are	 typically	 in	 the	 range	70–120%,	with	an	971 
associated	 repeatability	 RSD	 ≤	 20%,	 (e.g.,	 as	 established	 for	 pesticides	 in	972 
SANCO/12571/2013	(SANCO,	2013)).	973 
As	previously	described	in	this	review,	LC-MS	systems	are	most	widely	applied	in	974 
WBE	 studies.	 Yet,	matrix	 effects	 are	 one	 of	 the	main	 problems	 associated	with	 the	975 
correct	 determination	 of	 IDBs	with	 these	 techniques.	Matrix	 effects	 result	 from	 the	976 
competition	 between	 matrix	 co-eluting	 components	 and	 analytes	 in	 the	 ionization	977 
process	(Trufelli	et	al.,	2011).	This	competition	affects	quantification	of	the	analytes	and	978 
must,	therefore,	be	removed,	minimized,	or	corrected	for.	Quantification	with	matrix-979 
matched	calibration	is	suitable	and	is	frequently	used	in	some	research	fields,	where	a	980 
representative	 blank	 matrix	 can	 be	 easily	 obtained.	 However,	 the	 variability	 of	 the	981 
chemical	composition	of	wastewater	and	the	common	presence	of	some	compounds	in	982 
the	samples	used	as	“blank”	poses	difficulties	to	use	this	approach	in	WBE.	Instead,	the	983 
standard	additions	method	might	be	used,	but	it	would	imply	many	more	injections	in	984 
the	LC-MS	system,	apart	from	the	need	to	adjust	the	additions	accordingly	to	the	analyte	985 
concentration	 in	 the	 sample	 for	 appropriate	 application	 of	 this	 methodology.	986 
Furthermore,	 the	 high	 level	 of	 some	 compounds	 makes	 it	 problematic	 to	 maintain	987 
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linearity	in	the	calibration	curve.	Hence,	the	use	of	isotope-labelled	internal	standards	988 
(ILIS)	is	the	most	common	way	to	correct	for	matrix	effects,	but	also	for	potential	errors	989 
associated	with	sample	manipulation	and	storage	if	the	ILIS	is	added	to	the	sample	just	990 
after	sample	collection	(i.e.,	as	surrogate).	When	available,	the	use	of	a	labelled	analyte	991 
is	recommended	to	ensure	a	satisfactory	correction	of	matrix	effects.	However,	it	should	992 
be	 noted	 that,	 during	 method	 validation,	 there	 is	 an	 absolute	 need	 to	 thoroughly	993 
evaluate	if	the	labelled	IS	accurately	corrects	for	matrix	effects.	994 
The	estimation	of	limits	of	detection	(LODs)	and	limits	of	quantification	(LOQs)	995 
is	usually	performed	based	on	a	signal-to-noise	(s/n)	ratio	of	1:3	and	1:10,	respectively.	996 
More-realistic	LOQs	can	be	estimated	at	s/n	10	for	the	quantitation	transition,	but	also	997 
at	 s/n	 3	 for	 the	 qualification	 transition	 to	 ensure	 not	 only	 the	 quantification	 of	 the	998 
compound	but	 also	 its	 reliable	 identification	 (Bijlsma	 et	 al.,	 2014a).	 In	Orbitrap	 data	999 
processing,	noise	is	filtered	out.	Therefore,	the	common	s/n	approach	to	derive	LOQ	and	1000 
LOD	does	not	apply.	Instead,	LOQs	in	Orbitrap	MS	are	determined	based	on	the	lowest	1001 
concentration	of	an	ILIS	in	pure	water	that	produces	an	appreciable	signal	that	meets	1002 
the	identification	criteria	(Bijlsma	et	al.,	2013b;	de	Voogt	et	al.,	2011).	The	matrix	effect	1003 
is	calculated	from	the	ratio	of	the	responses	of	the	ILIS	in	the	matrix	and	in	pure	water	1004 
and	 used	 to	 calculate	 the	 actual	 LOQ	 in	 that	 matrix.	 Some	 guidelines,	 like	 SANCO,	1005 
defined	the	method	LOQ	as	 the	 lowest	spiking	 level	of	 the	validation	that	meets	 the	1006 
method	performance	acceptability	–	that	definition	is	a	stricter	criterion	that	can	also	1007 
be	 applied	 in	 WBE.	 Anyway,	 an	 estimation	 of	 LODs	 and	 LOQs	 in	 wastewater	 is	1008 
complicated,	 because	 notable	 variations	 in	 chemical	 composition	 between	 samples	1009 
occur.	Representative	matrix-matched	standards	cannot	be	easily	prepared,	due	to	the	1010 
presence	of	analytes	in	most	influent	samples,	and	because	of	the	variations	in	sample	1011 
composition	 from	 one	 sample	 to	 the	 other.	 This	 fact	 makes	 problematic	 a	 rational	1012 
comparison	 of	 these	 parameters	 among	 different	 published	 methodologies.	 An	1013 
estimation	 of	 LODs/LOQs	 from	 standards	 in	 solvent	 at	 least	 could	 make	 a	 fair	1014 
comparison	between	instrumental	performances,	although	not	analytical	methods.	An	1015 
efficient	and	realistic	approach	to	estimate	these	parameters	in	a	homogeneous	way	is	1016 
from	inter-laboratory	exercises	where	all	participants	analyze	the	same	samples	with	1017 
their	own	analytical	methodology.		1018 
41 
 
Confirmation	 of	 positives	 is	 an	 essential	 aspect	 in	 the	 analysis.	 To	 this	 aim,	1019 
guidelines	such	as	that	from	the	European	Commission	(European	Commission,	2002)	1020 
can	be	adopted,	where	the	confirmation	of	positive	findings	is	based	on	the	collection	1021 
of	identification	points	(IPs).	The	number	of	IPs	earned	depends	on	the	mass	analyzer	1022 
used.	Thus,	for	QqQ	low-resolution	instruments	used	in	tandem	MS,	a	minimum	of	two	1023 
transitions	should	be	monitored	for	a	safe	positive	finding,	whereas	in	high-resolution	1024 
instruments	at	least	two	ions	must	be	monitored.	In	addition,	the	accomplishment	of	1025 
the	ion	ratio	between	recorded	transitions	and	a	retention	time	within	the	maximum	1026 
tolerances	allowed	are	required.	1027 
Not	only	quantification,	but	also	confirmation	of	the	identity	could	be	affected	1028 
by	matrix	interferences.	As	stated	before,	two	transitions	(Q,	q)	are	normally	acquired	1029 
in	LC-MS/MS	analysis.	One	of	the	most-controversial	 issues	 is	the	accomplishment	of	1030 
the	ion	ratio	between	these	transitions	(q/Q	ratio)	required	for	confirmation.	Ion	ratios	1031 
in	samples	might	be	affected	by	matrix	components;	e.g.,	when	at	least	one	of	the	two	1032 
selected	SRM	transitions	is	shared	with	the	matrix,	which	might	lead	to	unexpected	ion	1033 
ratios	with	deviations	that	exceed	the	maximum	allowed.	This	situation	is	more	prone	1034 
to	happen	when	the	specificity	of	the	neutral	losses	involved	in	the	selected	transitions	1035 
is	not	evaluated	and	common	losses,	such	as	the	loss	of	H2O	or	CO2,	are	implicated.	Non-1036 
specific	 transitions	 are	 a	 weakness	 not	 yet	 tackled	 with	 the	 current	 guidelines	 and	1037 
should	be	considered	in	this	research	field	(Delatour	et	al.,	2007).	In	this	situation,	the	1038 
acquisition	of	all	available	transitions	is	recommended	to	facilitate	confirmation	of	the	1039 
positives	by	testing	the	additional	transitions	acquired.	In	cases	of	non-compliance,	the	1040 
sample	might	be	reported	as	positive,	but	include	a	comment	on	the	non-compliance	of	1041 
the	ratio,	and	report	the	actual	q/Q	ratio	deviation	obtained.	Additional	work	would	be	1042 
necessary	to	test	if	any	interfering	compound	actually	affected	the	q/Q	ratio.	1043 
During	a	recent	inter-laboratory	study	undertaken	by	the	SCORE	group,	one	of	1044 
the	questions	raised	related	to	the	significant	variations	in	q/Q	ratios	reported	by	the	1045 
different	participants	(Castiglioni	et	al.,	2013),	even	with	the	same	SRM	transitions.	As	1046 
an	example,	for	cocaine,	with	304	>	182	(Q)	and	304	>	82	(q),	ion	ratios	from	different	1047 
laboratories	ranged	from	0.12	to	0.38,	and	seemed	to	notably	depend	on	the	instrument	1048 
used	 and	 on	 the	 parameters	 optimized	 in	 each	 laboratory	 (e.g.,	 cone	 and	 collision	1049 
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voltages).	 In	 addition,	 some	 variations	 from	 batch	 to	 batch	 were	 also	 observed.	1050 
Nevertheless,	 these	 variations	 were	 not	 relevant	 to	 confirm	 identity,	 because	 it	 is	1051 
recommended	 that	 q/Q	 ratios	 are	 measured	 and	 evaluated	 for	 accomplishment	 by	1052 
every	laboratory	within	each	sample	batch	with	the	standards	included	in	the	sequence	1053 
of	sample	analysis.	1054 
Apart	 from	the	validation	of	the	method	 in	each	 laboratory	before	 its	routine	1055 
use,	the	use	of	internal	quality	controls	(QCs)	is	of	primary	importance	to	track	possible	1056 
daily	method	variations.	In	theory,	an	internal	QC	is	a	final	check	of	the	correct	execution	1057 
of	all	the	processes	that	are	included	in	the	analytical	protocol.	Due	to	the	difficulties	to	1058 
obtain	blank	wastewater	samples,	those	with	the	lowest	concentrations	expected	are	1059 
preferred	to	prepare	spiked	samples	used	as	internal	QCs.	This	means	that	samples	from	1060 
locations	with	low	drug	use	and/or	collected	in	the	mid-week,	where	the	consumption	1061 
of	illicit	drugs	is	expected	to	be	lower	than	in	the	weekends,	would	fit	better	to	prepare	1062 
the	QCs.	Despite	this	fact	that	low	concentrations	of	IDBs	are	expected,	samples	selected	1063 
should	 be	 analyzed	 to	 accurately	 know	 the	 potential	 analyte	 concentration	 in	 these	1064 
“blank”	samples,	in	order	to	be	subtracted	from	the	QC	prepared.	Although	there	is	no	1065 
guideline	in	this	field,	QCs	individual	recoveries	from	60	to	140%	might	be	acceptable	in	1066 
wastewater	 analysis,	 as	 suggested	 in	 the	 SANCO	 guidelines	 (SANCO,	 2013).	 Other	1067 
guidelines	recommend	an	acceptable	range	of	80-120%	at	the	LOQ	level	(EMA,	2012).	1068 
When	QC	recoveries	are	out	of	this	interval,	the	sample	sequence	of	analysis	should	be	1069 
repeated.	If	the	problem	persists,	then	appropriate	measures	should	be	taken	to	ensure	1070 
the	accuracy	of	the	method.	1071 
The	 implementation	 of	 quality	 assurance	 practices	 to	 analytical	 chemistry	 is	1072 
recognized	 as	 a	 prerequisite	 to	 produce	 data	 with	 known	 metrological	 qualities.	1073 
Regardless	of	the	target	analyte	or	sample	type,	quality	assurance	and	quality	control	1074 
are	 the	 cornerstones	 to	 analytical	 data	 validation.	 In	 addition	 to	 daily	 internal	1075 
performance	verifications	via	QC	materials,	a	good	quality	assurance	plan	should	include	1076 
regular	external	performance	evaluations	for	an	independent	assessment	of	analytical	1077 
proficiency.	The	goal	of	inter-laboratory	studies	is	to	demonstrate	that	participation	in	1078 
this	exercise	 leads	 to	 improved	quality	of	analytical	 results.	The	results	are	of	crucial	1079 
interest	for	laboratories	because	these	provide	clear	information	of	their	measurement	1080 
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capabilities.	It	has	to	be	pointed	out	that	participation	is	either	voluntary	or	forced	by	1081 
external	 requirements	 (e.g.,	 legal,	 accreditation,	 control	 bodies).	 Inter-laboratory	1082 
exercises	involve	comparison	of	participants’	results	on	a	set	of	spiked	water	samples.	1083 
Care	needs	 to	be	taken,	 to	ensure	concentrations	are	equal	 in	all	aliquots,	especially	1084 
when	particulate	matter	should	also	be	analyzed.	This	also	holds	true	when	subsampling	1085 
from	composite	samples	(Capel	and	Larson,	1996).	The	separate	results	are	compared	1086 
with	the	median	of	the	entire	group	to	determine	the	accuracy	of	the	method	used.	By	1087 
using	a	set	of	two	samples	spiked	at	different	levels	with	the	same	compound	a	so	called	1088 
Youden	pair	is	created.	Visualization	of	these	results	in	a	Youden	plot	show	within-	and	1089 
between-laboratory	 variability.	 Also	 individual	 constant	 errors	 become	 visible,	 and	1090 
random	errors	and	systematical	errors	can	be	recognized.		1091 
Several	 inter-laboratory	 studies	 have	 been	 organized	 by	 the	 SCORE	 group	 on	1092 
selected	IDBs	regularly	monitored	in	WBE.	In	the	period	2011-2015	five	consecutive	sets	1093 
of	interlaboratory	exercises	have	been	organized,	initially	with	methanolic	solutions	of	1094 
analytes	 that	 gradually	 moved	 to	 more-complicated	 matrices	 such	 as	 extracts	 and	1095 
genuine	wastewater	samples.	These	were	the	first	inter-laboratory	exercises	organized	1096 
to	determine	IDBs	in	wastewater.	The	results	of	this	stepwise	inter-laboratory	testing	1097 
and	 the	 improvements	 made	 during	 this	 five-year	 period	 can	 help	 to	 optimize	 the	1098 
analytical	procedures	of	participating	laboratories	and	aid	in	a	reliable	interpretation	of	1099 
WBE	data.	To	this	end,	concentrations	of	IDBs	in	wastewater	provided	by	laboratories	1100 
that	didn’t	perform	well	in	the	interlaboratory	exercises	were	not	taken	into	account;	1101 
however,	together	with	experts	in	the	field,	solutions	for	the	analytical	deviations	are	1102 
sought.	1103 
	1104 
8. General	summary	and	perspectives	1105 
The	 investigation	 of	 IDBs	 in	 wastewater	 is	 a	 subject	 of	 current	 interest	 in	1106 
analytical	chemistry.	The	complexity	of	the	matrix	under	investigation,	the	low	analyte	1107 
concentrations	 commonly	 found,	 and	 the	 need	 to	 detect	 and	 quantify	 not	 only	 the	1108 
parent	compounds	but	also	the	main	metabolites	of	drugs,	make	this	task	an	analytical	1109 
challenge.	 In	 addition,	 human	metabolism	 is	 not	 always	well	 known,	 and	 the	 target	1110 
biomarkers	might	be	unknown.	In	this	field,	liquid	chromatography	combined	with	low-	1111 
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and	high-resolution	MS	is	an	indispensable	tool.	Different	strategies	can	be	applied	to	1112 
investigate	IDBs	in	wastewater	(discussed	in	this	review)	from	quantification	of	target	1113 
compounds	to	the	detection	and	(tentative)	identification	of	unknown	metabolites	and	1114 
TPs.	1115 
Quantification	of	IDBs	in	wastewater	is	a	requisite	in	WBE	in	order	to	estimate	1116 
drug	use	in	populations.	However,	the	presence	of	drug	residues	in	wastewater	also	has	1117 
other	 implications.	 For	 example,	 there	 is	 a	 possible	 environmental	 impact	 when	1118 
compounds	 are	 not	 completely	 removed	 by	WWTPs.	 Indeed,	 low	 removal	 rates	 for	1119 
certain	 illicit	 drugs,	 such	 as	MDMA,	 ketamine,	 and	methadone,	 have	 been	 observed	1120 
(Bijlsma	et	al.,	2012).	Thus	low	removal	rates	implies	that	drug	residues	can	be	present	1121 
in	 effluent	 wastewater,	 and	 finally	 reach	 the	 aquatic	 environment.	 Therefore,	 the	1122 
determination	of	illicit	drugs	and	metabolites	in	effluent	wastewater	and	surface	water	1123 
is	also	of	interest,	as	well	as	the	investigation	of	potential	TPs	that	can	be	formed	in	the	1124 
environment.	Here,	concentration	 levels	are	much	 lower	than	 in	 influent	wastewater	1125 
and,	therefore,	excellent	sensitivity	is	required	for	the	analytical	methods.	1126 
In	 this	 field,	under	continuous	development,	several	 trends	and	needs	can	be	1127 
highlighted:	1128 
1) There	is	a	need	to	increase	the	knowledge	of	metabolites	that	might	be	present	1129 
in	 the	 aquatic	 environment.	 Especially	 for	NPS,	 there	 is	 a	 lack	 of	metabolism	1130 
studies,	and	target	compounds	are	still	not	fully	identified.	Here,	the	use	of	HRMS	1131 
is	 highly	 promising	 due	 to	 its	 potential	 to	 detect	 and	 identify	 drug-related	1132 
compounds	 to	 make	 use	 of	 different	 approaches,	 such	 as	 the	 “common	1133 
fragmentation	pathway”,	which	is	very	useful	to	find	parent-chemically	related	1134 
compounds.	Advantageously,	a	retrospective	analysis	can	be	made	at	any	time	1135 
from	HRMS	 data	 to	 facilitate	 the	 search	 of	 compounds	 of	 interest	 (e.g.,	 new	1136 
discovered	metabolites)	in	samples	previously	analyzed.	Furthermore,	from	the	1137 
perspective	of	environmental	chemistry,	it	is	of	interest	to	extend	this	research	1138 
to	TPs,	which	in	many	occasions	are	still	unknown.	1139 
2) The	development	of	wide-scope	screening	will	surely	be	one	of	the	key	features	1140 
of	HRMS	in	the	next	few	years.	The	use	of	 long	lists	of	selected	compounds	is	1141 
essential	 to	 facilitate	 target	 screening	 with	 or	 without	 (suspect	 screening)	1142 
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reference	 standards.	 To	maintain	 the	 “universality”	 of	 this	 approach,	 generic	1143 
sample	 treatments	 would	 be	 required	 in	 order	 to	 avoid	 potential	 losses	 of	1144 
analytes	during	sample	handling.	Some	problematic	compounds,	mainly	those	1145 
present	in	ionic	form,	will	always	require	specific/individual	methods,	because	1146 
they	cannot	be	included	in	multi-residue/multi-class	methodologies,	due	to	their	1147 
special	physico-chemical	characteristics.	1148 
3) In	line	with	the	previous	point,	it	is	expected	to	widen	future	screening	to	include	1149 
NPS.	 However,	 it	 will	 not	 be	 easy	 to	 obtain	 satisfactory	 results	 in	 this	 case	1150 
because	 of	 two	main	 limitations:	 i)	 very	 low	 concentrations	 expected	 in	 the	1151 
samples	as	a	consequence	of	the	limited	use	of	these	compounds	in	comparison	1152 
with	 “conventional”	 drugs,	 such	 as	 cocaine,	 cannabis,	 or	 amphetamines;	 ii)	1153 
continuous	appearance	of	new	NPS	with	changes	in	the	chemical	structure	that	1154 
complicate	their	detection	and	identification.	Related	to	the	last	point,	HRMS	will	1155 
be	a	powerful	tool	to	identify	NPS	and	unknown	metabolites.	1156 
4) The	combination	of	non-biased	and	biased	non-target	analysis	with	HRMS	will	1157 
be	one	of	the	key	research	fields	 in	the	near	future.	Hopefully,	 this	combined	1158 
approach	 will	 allow	 one	 to	 discover	 new	 compounds	 of	 interest,	 such	 as	1159 
unknown	 or	 non-searched	 metabolites,	 TPs	 and/or	 new	 drugs.	 Their	 low	1160 
concentrations	 in	most	 cases	will	 be	 an	 extra	 difficulty	 to	 obtain	 satisfactory	1161 
results.	1162 
5) LC-MS/MS	 with	 triple	 quadrupole	mass	 analyzers	 will	 still	 be	 the	 reference	1163 
technique	to	quantify	selected	IDBs	in	target	methodologies,	due	to	its	excellent	1164 
sensitivity	 and	 selectivity.	 However,	 new	 instruments	 with	 improved	1165 
performances	will	widen	the	number	of	compounds	included	in	the	method	up	1166 
to	 several	 hundreds.	 The	 incomparable	 sensitivity	 reached	 with	 this	1167 
instrumentation	will	obtain	data	on	the	presence	of	NPS	in	wastewaters,	with	1168 
expected	concentrations	at	the	pg/L	level.	1169 
6) A	 common	 protocol	 of	 action	 should	 be	 used	 in	 WBE	 studies	 to	 produce	1170 
homogeneous	 and	 comparable	 data	 at	 different	 sites	 and	 provide	 the	 most	1171 
reliable	estimates	of	drug	use.	Uncertainty	factors	associated	with	the	different	1172 
steps	involved	in	WBE	(sampling,	chemical	analysis,	stability	of	drug	biomarkers	1173 
in	sewage,	back-calculation	of	drug	use,	estimation	of	population	size)	have	to	1174 
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be	considered	in	order	to	reduce	and/or	minimize	the	uncertainty	of	the	entire	1175 
procedure	(Castiglioni	et	al.,	2013).	A	best	practice	protocol	has	been	recently	1176 
proposed	and	adopted	by	Europe-wide	studies.	Three	phases	of	the	approach	1177 
are	included:	sampling	and	sample	handling,	storage	treatment	during	sampling,	1178 
chemical	analysis-quality	 control	 (EMCDDA,	2016).	Currently,	 the	most-urgent	1179 
needs	 for	 future	 research	are:	1)	 improve	 the	quality	of	chemical	analyses	by	1180 
following	specific	quality	requirements;	2)	improve	the	knowledge	on	stability	of	1181 
IDBs	 in-sewer;	 3)	 plan	 additional	 pharmacokinetic	 studies	 to	 produce	 reliable	1182 
human	excretion	profiles	for	IDBs;	4)	explore	novel	possibilities	to	estimate	the	1183 
population	size	in	a	catchment.	1184 
7) The	improved	characteristics	of	HRMS	instruments,	mainly	sensitivity	and	linear	1185 
dynamic	range,	will	make	this	technique	attractive	for	quantitative	analysis	as	1186 
well.	The	search	 for	 the	desired	“All-in-One”	method	and	 instrument	will	 still	1187 
continue	in	the	coming	years,	because	combination	of	all	desired	features	in	just	1188 
one	 method/instrument	 is	 an	 exciting	 issue:	 qualitative	 and	 quantitative	1189 
analysis,	 with	 possibilities	 for	 structural	 elucidation	 of	 unknowns.	 Future	1190 
developments	of	HRMS	will	surely	be	related	to	scan-speed	improvements	for	1191 
Orbitrap,	which	for	example	will	allow	more	efficient	combination	to	UHPLC,	or	1192 
GC,	whereas	improvements	in	TOF	MS	analyzers	will	increase	the	mass-resolving	1193 
power.	Advances	will	include	development	of	tribrid	analyzers	that	incorporate	1194 
new	possibilities	such	as	Ion	Mobility	Spectrometry.	Improvements	in	accurate-1195 
mass	 full-acquisition	 data	 processing	 with	 more-powerful	 and	 user-friendly	1196 
software	are	also	expected.	 In	the	near	future,	we	will	see	a	growth	of	HRMS	1197 
applications,	not	only	 in	WBE,	but	also	 in	other	 fields,	 such	as	environmental	1198 
research,	food-safety,	toxicology	and	doping	control	analysis	1199 
8) It	 will	 be	 necessary	 to	 harmonize	 the	 criteria	 for	 reliable	1200 
identification/confirmation	 of	 compounds	 detected	 in	 samples.	 Relevant	1201 
parameters,	as	the	number	and	specificity	of	ions	required,	maximum	ion-ratio	1202 
deviations	allowed,	mass	errors	accepted	are	needed	to	facilitate	comparison	of	1203 
data	and	to	avoid	false	positives	or	negatives	due	to	the	use	of	dissimilar	criteria	1204 
among	different	authors.	1205 
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9) The	 limits	of	detection	and/or	quantification	of	the	methods	 is	a	requisite	to	1206 
perform	realistic	comparison	of	data	in	WBE	studies.	The	non-detection	might	1207 
be	translated	to	figures	that	depend	on	the	LOD;	i.e.,	the	method	sensitivity.	The	1208 
comparison	 of	 drug	 consumption	 among	 populations	 makes	 use	 in	 some	1209 
occasions	 of	 very	 low	 concentration	 data	 for	 less-consumed	 drugs;	 this	1210 
comparison	might	be	distorted	with	unrealistic	LOD/LOQ	data.	There	is	a	need	1211 
to	harmonize	criteria	for	their	estimation	in	WBE.		1212 
10) Further	 development	 of	 chiral	 analytical	 methods	 and	 wider	 application	 of	1213 
enantiomeric	 profiling	 of	wastewater	 are	 expected	 in	 the	 coming	 years.	 This	1214 
expectation	 is	 because	 enantiomeric	 profiling	 of	 illicit/abused	 drugs	 in	1215 
wastewater	 represents	a	powerful	 tool	 to	allow	one	 to	differentiate	between	1216 
consumption	 and	 disposal	 of	 unused	 drugs	 or	 production	 waste	 in	 WBE.	1217 
Advances	are	needed	in	the	design	of	new,	more-robust	stationary	materials	to	1218 
separate	multi-residue	mixtures	of	chiral	drugs	within	a	shorter	method	time.	1219 
11) A	wastewater	validation	guideline,	based	on	the	existing	guidelines,	 is	desired	1220 
including	key	aspects	related	to	quality	control	that	must	be	carefully	considered	1221 
in	WBE.	 Internal	 and	 external	 quality	 controls	 are	 both	 needed	 for	 a	 reliable	1222 
analytical	 methodology.	 The	 organization	 of	 interlaboratory	 exercises	 are	1223 
imperative	 from	 two	perspectives:	 i)	 to	produce	 reliable	WBE	data,	 and	 ii)	 to	1224 
improve	analytical	performance	of	participating	laboratories.		1225 
12) The	 ultimate	 goal	 of	WBE	 is	 to	 provide	 results	 in	 real-time.	 This	 data	 can	 be	1226 
achieved	 with	 biosensors.	 Biosensors	 have	 already	 been	 applied	 in	 WBE	 to	1227 
screen	PSA,	 prostate	 cancer	biomarker	 (Yang	et	 al.,	 2015c),	DNA	 (Yang	et	 al.,	1228 
2015a),	and	cocaine	(Yang	et	al.,	2016).	There	are,	however,	several	issues	that	1229 
need	 to	 be	 addressed;	mainly	 the	 relatively	 low	 sensitivity	 of	 biosensors	 and	1230 
most	 probably	 low	 selectivity.	 Due	 to	 fast	 advancements	 in	 the	 field,	 wide	1231 
application	of	biosensors		in	WBE	is	envisaged	(Yang	et	al.,	2015b).	1232 
13) The	potential	of	WBE	will	be	expanded	to	other	aspects	of	public	health.	Sewage	1233 
contains	 a	 hidden	 wealth	 of	 highly	 complex	 chemical	 information	 about	1234 
biological	processes	 that	occur	 in	 the	human	body	 (Daughton,	2011).	 Specific	1235 
biomarkers	could	serve	as	indicators	of	exposure,	stress,	vulnerability	to	disease,	1236 
acquired	 disease,	 or	 health.	 Biomarkers	 include	 endogenous	 compounds	1237 
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produced	in	response	to	stress	or	indicative	of	health,	adducts	of	endogenous	1238 
chemicals	 and	 xenobiotics,	 or	 metabolites	 of	 detoxification	 or	 intoxication	1239 
processes	 from	 xenobiotic	 exposure	 (Daughton,	 2012).	 Theoretically,	 such	1240 
biomarkers	 could	 serve	 as	 collective	 measures	 of	 community-wide	 health	 or	1241 
disease,	and	could	provide	a	means	to	conduct	epidemiology	in	near-real	time.	1242 
It	has,	therefore,	the	capability	to	serve	as	an	early-warning	system	in	pandemics	1243 
(Ort	et	al.,	2014a).	Quantitative	analysis	of	‘health	biomarkers’	in	sewage	might	1244 
allow	one	 to	monitor	 changes	over	 time;	 for	example,	 in	 response	 to	 specific	1245 
campaigns,	 identification	 of	 trends	 and,	 inter-community	 comparisons	 in	1246 
relation	to	their	health,	diet,	lifestyle,	and	environment	(Thomas	and	Reid,	2011).		1247 
14) It	is	essential	to	widen	the	knowledge	on	selection	of	the	most-appropriate	IDB	1248 
in	WBE	and	to	take	into	account	specific	requirements	that	a	proper	biomarker	1249 
should	fulfil	 in	order	to	ensure	the	reliability	of	the	back-calculated	estimates.	1250 
The	main	 requirements	 for	 an	 IDB	 are:	 1)	 excretion	 in	 consistent	 amounts	 in	1251 
urine;	 2)	 detectable	 in	 urban	wastewater;	 3)	 stable	 in	wastewater;	 4)	 human	1252 
excretion	 as	 unique	 source.	 These	 characteristics	 are	 essential	 to	 perform	 a	1253 
reliable	quantitative	analysis	of	the	substance	under	investigation	and	should	be,	1254 
therefore,	carefully	considered	in	future	studies	to	select	new	IDBs.		1255 
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